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Abstract 
Objective: To provide a comprehensive meta-analysis on the efficacy of psychological and 
medical treatments for binge-eating disorder (BED), including those targeting weight loss. 
Method: Through a systematic search before March 2018, 81 published and unpublished 
randomized-controlled trials (RCTs), totaling 7,515 individuals with BED (DSM-IV, DSM-
5), were retrieved and analyzed using random-effect modeling. Results: In RCTs with 
inactive control groups, psychotherapy, mostly consisting of cognitive-behavioral therapy, 
showed large-size effects for the reduction of binge-eating episodes and abstinence from 
binge eating, followed by structured self-help treatment with medium-to-large effects when 
compared to wait-list. Pharmacotherapy and pharmacological weight loss treatment mostly 
outperformed pill placebo conditions with small effects on binge-eating outcome. These 
results were confirmed for the most common treatments of cognitive-behavioral therapy, self-
help treatment based on cognitive-behavioral therapy, and lisdexamfetamine. In RCTs with 
active control groups, there was limited evidence for the superiority of one treatment category 
or treatment. In a few studies, psychotherapy outperformed behavioral weight loss treatment 
in short- and long-term binge-eating outcome and led to lower longer-term abstinence than 
self-help treatment, while combined treatment revealed no additive effect on binge-eating 
outcome over time. Overall study quality was heterogeneous and the quality of evidence for 
binge-eating outcome was generally very low. Conclusions: This comprehensive meta-
analysis demonstrated the efficacy of psychotherapy, structured self-help treatment, and 
pharmacotherapy for patients with BED. More high quality research on treatments for BED is 
warranted, with a focus on long-term maintenance of therapeutic gains, comparative efficacy, 
mechanisms through which treatments work, and complex models of care. 
Keywords: Meta-analysis; binge-eating disorder; treatment; intervention   
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Public Health Significance Statement 
This comprehensive meta-analysis on psychological and medical treatments for binge-eating 
disorder demonstrates the efficacy of psychotherapy, structured self-help treatment, and 
pharmacotherapy. Psychotherapy may be prioritized over behavioral weight loss treatment, 
self-help treatment, and combined treatment. These results can be used as guidance in 
translating evidence-based treatments into clinical practice. 
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Binge-eating disorder (BED), characterized by recurrent binge eating that occurs in the 
absence of regular inappropriate compensatory behaviors, was first included as its own 
diagnostic entity in the Fifth Edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5; American Psychiatric Association [APA], 2013). Extant literature has 
indicated BED to be associated with severe health impairments, including increased eating 
disorder and general psychopathology, mental disorder comorbidity, obesity and associated 
medical sequelae, and decreased quality of life (Kessler et al., 2013; Mitchell, 2016; Wilfley, 
Citrome, & Herman, 2016). With a lifetime prevalence rate of 1.9%, BED is the most 
common eating disorder, typically developing in adolescence or early adulthood (Kessler et 
al., 2013; Swanson, Crow, Le Grange, Swendsen, & Merikangas, 2011). An increasing 
number of clinical studies evaluating the outcome of diverse treatment approaches to BED has 
been published and compiled in meta-analyses and systematic reviews (e.g., Berkman et al., 
2015; Brownley et al., 2016; Ghaderi et al., 2018; Hay, 2013; Hay & Claudino, 2012; 
Linardon, Wade, de la Piedad Garcia, & Brennan, 2017; McElroy, Guerdjikova, Mori, & 
O'Melia, 2012; Palavras, Hay, & Claudino, 2017; Reas & Grilo, 2008, 2015; Stefano, 
Bacaltchuk, Blay, & Appolinario, 2008; Vocks et al., 2010), informing evidence-based 
clinical guideline development (e.g., Association of the Scientific Medical Societies 
[AWMF], 2010; National Institute for Health and Care Excellence [NICE], 2017) that are 
aimed at guiding the translation of clinical research into practice (for review see Hilbert, 
Hoek, & Schmidt, 2017). 
 Three comprehensive meta-analyses examined several broader treatment categories in 
BED: Vocks et al. (2010) analyzed 38 treatment studies with prospective randomized-
controlled (RCTs), non-randomized-controlled, or uncontrolled designs, searched up to June 
2006. In examining post-treatment effects in the 21 RCTs, they found that psychotherapy and 
structured self-help treatment, both mostly based on cognitive-behavioral therapy (CBT), led 
to greater improvements in binge eating and eating disorder psychopathology than wait-list. 
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In RCTs, pharmacotherapy - mainly antidepressants - improved binge eating more than pill 
placebo, but did not improve eating disorder psychopathology. Both psychotherapy and 
pharmacotherapy significantly reduced depression when compared to inactive control 
conditions. Psychotherapy, self-help treatment, and pharmacotherapy did not lead to 
significant changes in body weight, and drop-out rates did not differ from those in inactive 
control conditions. The limitations of this meta-analysis included its lack of a risk of bias 
assessment, adverse events examination, and systematic documentation of the search process. 
The comparative efficacy of treatment categories was evaluated in indirect comparisons only, 
not accounting for patient, treatment, or setting characteristics that differ between categories.  
 More recently, a comprehensive systematic review and meta-analysis of 34 
psychological and pharmacological RCTs for BED searched up to November 2015 (for 
MEDLINE up to May 2016) confirmed greater rates of abstinence from binge eating in CBT 
than in inactive control conditions at post-treatment (Berkman et al., 2015; Brownley et al., 
2016). Furthermore, second-generation antidepressants and the central nervous stimulant 
lisdexamfetamine were superior to pill placebo for binge eating and eating disorder 
psychopathology, and the former also demonstrated a significant improvement in depression. 
Studies with high risk of bias were excluded, and the comparisons were based on a low 
number of studies and treatment categories, limiting this study’s utility for clinical guideline 
development. Similar limitations apply to the meta-analysis by Ghaderi et al. (2018) based on 
45 RCTs searched up to November 2016, also excluding studies with a high risk of bias. This 
study confirmed a significantly greater efficacy of CBT and CBT self-help treatment for 
improving binge eating, eating disorder psychopathology, and depression, but not body mass 
index (BMI, kg/m2) when compared to wait-list. When compared to pill placebo, greater 
effects were found for selective serotonin reuptake inhibitors on binge eating, but not on 
depression and BMI, and for lisdexamfetamine on binge eating and BMI. While for Brownley 
et al.’s (2016) study, the comparative efficacy was quantified indirectly in a network meta-
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analysis of pharmacotherapy studies only (Peat et al., 2017), Ghaderi et al. (2018) examined a 
few active treatment comparisons, however, collapsing treatment categories (e.g., CBT and 
CBT self-help treatment), which thus limits specificity of findings.  
 In contrast to these comprehensive meta-analyses, other meta-analyses specifically 
focused on a few categories of treatment for BED, for example, pharmacotherapy (Reas & 
Grilo, 2008), especially antidepressants (Stefano et al., 2008) or lisdexamfetamine (Fornaro et 
al., 2016), structured self-help (Beintner, Jacobi, & Schmidt, 2014; Traviss‐Turner, West, & 
Hill, 2017), CBT or CBT self-help (Linardon, Wade et al., 2017), or mixed cognitive-
behavioral applications and behavioral WLT (Palavras et al., 2017). With such a narrow focus 
on treatment categories, these studies have limited value for evidence-based clinical guideline 
development. The comparative efficacy of diverse treatments is key in this context: Head-to-
head comparisons are suited to elucidate the potency of a treatment directly in relation to 
another treatment and can help to clarify treatment specificity. However, while one previous 
meta-analysis based on direct comparisons found some comparative efficacy of CBT versus 
other psychotherapies or pharmacotherapy on binge-eating outcome (Linardon, Fairburn, 
Fitzsimmons-Craft, Wilfley, & Brennan, 2017), others did not (Linardon, Wade et al., 2017; 
Spielmans et al., 2013). Further clarification on comparative efficacy is thus warranted, 
ideally broadening the focus to other treatment categories. In addition, it remains unclear to 
what extent treatment efficacy varies by patient or treatment characteristics, or by 
methodological aspects including study quality. So far, only few moderators of treatment have 
been assessed previously for BED, with inconclusive results (Linardon, de la Piedad Garcia, 
& Brennan, 2017). 
 In light of an increasing number of clinical studies of BED and/or long-term follow-
ups, it is thus timely and relevant to update, refine, and extend the evidence on the efficacy of 
psychological and medical treatments by: (1) adding all available treatment categories, 
considering those that have been examined for BED, but have not been part of previous 
Meta-analysis of treatments for binge-eating disorder 8 
comprehensive meta-analyses, in order to examine their short- and long-term efficacy; (2) 
conducting direct comparisons of treatments in order to further clarify whether one treatment 
outperforms another; and (3) facilitating moderator analyses that indirectly explore patient, 
treatment, and methodological characteristics and study quality in relation to treatment 
outcome. Thus, the present meta-analysis sought to assess and compare the efficacy of 
psychological and medical treatments for individuals with BED in RCTs regarding binge 
eating, eating disorder and general psychopathology, and body weight; to determine adverse 
events and treatment drop-out; and to examine risk of bias and moderators.  
Methods 
Registration and Search 
 This study, building upon the meta-analysis by Vocks et al. (2010), was registered in 
the PROSPERO International Prospective Register of Systematic Reviews 
(CRD42016043604). Methodological detail is given elsewhere (Hilbert et al., 2017).  
 The search strategy included terms related to binge eating and diverse forms of 
psychological and medical interventions in title, abstract, and keywords (or full texts): (binge 
eat*) AND (efficac* OR effect* OR outcome OR counsel* OR interven* OR pharmaco* OR 
drug OR psychoanaly* OR psychotherap* OR therap* OR treat* OR train* OR weight loss 
OR weight reduction OR self-help OR bariatric surg* OR weight loss surg* OR weight 
reduction surg* OR obesity surg*). Language was restricted to English. Published, 
unpublished, and ongoing studies from inception to February 2018 were sought.  
 The search was conducted independently by two psychologists (M.Sc. level), who 
resolved disagreement through consensus. The search was conducted in (1) electronic 
databases (AMED, ANNUAL REVIEWS, CDSR, CINAHL, Clinical Psychology Review, 
DARE, EMBASE, LILACS, MEDLINE, NIHR Centre for Reviews and Dissemination, 
PsycINFO, PubMED, PUBPSYCH, Web of Science); (2) national and international trials 
registers (CenterWatch Clinical Trials Listing Service, CENTRAL, ClincalTrials.gov, 
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Community Research and Development Information Service of the European Union, 
Deutsches Register Klinischer Studien, EU Clinical Trials Register, European Medicines 
Agency, Hong Kong Clinical Trials Register, ISRCTN Trial Registry, PROSPERO, South 
African National Clinical Trial Register, UK Clinical Trials Gateway, WHO International 
Clinical Trials Registry Platform); (3) pharmaceutical industry trials registers (AstraZeneca 
Clinical Trials, Eli Lilly and Company Clinical Trial Registry, GlaxoSmithKline Clinical 
Trial Register, NovartisClinicalTrials.com); and (4) through manual searches (reference lists 
of included studies and review articles identified during the search, and publications in the 
International Journal of Eating Disorders from 1990 to February 2018). Authors of ongoing 
studies were contacted.  
Study Selection 
 We included: (1) psychological (e.g., psychotherapy, self-help treatment) and medical 
(e.g., pharmacotherapy, bariatric surgery) treatment studies that were (2) applied to 
individuals with a pre-treatment diagnosis of BED according to DSM-IV (APA, 1994) or 
DSM-5 (including BED of low frequency and/or limited duration; APA, 2013); (3) used an 
RCT design; (4) assessed the core symptomatology of BED (binge-eating episodes or days, 
abstinence from binge eating, and/or diagnosis of BED); (5) provided sufficient detail to 
allow the calculation of effect sizes (e.g., M, SD and/or n, % at pre-treatment and post-
treatment or follow-up(s)), including a pre-treatment and at least one post-treatment or follow-
up assessment; (6) provided separate data reports for patients with BED in studies examining 
multiple patient groups; and (7) were written in English. Excluded were: (1) double reports of 
the same trial; and (2) case reports and studies with a sample size smaller than n = 10. 
 The screening process was conducted in two steps: (1) Two psychologists (M.Sc. 
level) independently reviewed all abstracts and titles for eligibility. Based on automatic and 
manual screening, double publications of the same trial were excluded. Disagreement was 
resolved through consensus. If deemed eligible or where eligibility was unclear, full-text 
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reports were obtained. (2) The two psychologists independently assessed all full-text reports 
for inclusion. Where unclear because of a lack of information, study authors were contacted. 
Disagreement was resolved by consensus and under supervision of the first author. Additional 
publications referred to in the primary included paper were obtained. Multiple reports within 
the framework of one study were assembled in order to form one unit of analysis.  
Data Extraction 
 The standardized coding scheme and handbook used by Vocks et al. (2010) with 
evidence of good interrater reliability was extended and updated. The handbook provides 
definitions, coding instructions, examples, and an overview of data management. Data 
extraction was performed independently by two trained psychologists (M.Sc. level). Data 
collection referred to: Eligibility, study design, inclusion and exclusion criteria, participant 
characteristics (e.g., sociodemographics according to PROGRESS: Place, Race, Occupation, 
Gender, Religion, Education, Socioeconomic status, Social status; O'Neill et al., 2014), time 
points of assessment, sample size, intervention characteristics (e.g., duration, integrity), 
outcomes, drop-out, adverse events, and risk of bias. The Cochrane Collaboration’s Risk of 
Bias Tool (Higgins & Green, 2011) was used to assess the risk of bias in published studies. 
All available information reported in text, tables, or figures was extracted. In order to retrieve 
missing data, authors were contacted. Missing data were coded as such, but not imputed.  
 Interrater reliability, determined for the primary outcome variables (see below), was 
almost perfect with 95% agreement between raters. Disagreement between raters was 
resolved through consensus and in consultation with the first author. In order to evaluate 
consistency with Vocks et al. (2010), interstudy reliability was determined for the primary 
outcome variables, and was almost perfect with 93% agreement between ratings.  
Outcome Measures 
 Primary outcomes were the number of binge-eating episodes and abstinence from 
binge eating. Binge-eating episodes are defined as eating an amount of food that is definitely 
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larger than what other people would eat under similar circumstances, associated with a sense 
of loss of control over eating (APA, 2013). The number of episodes rather than the number of 
days with binge-eating episodes were reported because of their representation in the DSM-5 
diagnostic criteria and greater availability of data. Abstinence from binge eating was defined 
as zero binge-eating episodes over a specified time frame. Diagnosis of BED according to 
DSM-IV (APA, 1994) or DSM-5 (APA, 2013) was not reported because of a lack of data. 
 As secondary outcomes, eating disorder psychopathology was operationalized through 
attitudes regarding eating behavior and body image, and general psychopathology was 
operationalized through measures of depression (see Hilbert et al., 2017). Body weight and 
BMI (kg/m2) were considered if based on objective measurement. Adverse events and drop-
out from treatment were recorded and categorized (cf. Berkman et al., 2015).  
 A considerable heterogeneity of instruments were used. If more than one instrument 
was used per outcome, the selection of one instrument per study followed a unified 
hierarchical strategy, unlike in Vocks et al. (2010): Generally, interview measures were 
prioritized over self-report measures. From these, instruments providing a multidimensional 
assessment were prioritized over those providing a unidimensional assessment, which applied 
to eating disorder psychopathology and depression only.  
Meta-Analyses  
First, in between-group analyses, the pre- to post-treatment and/or follow-up effect 
was compared for active treatment versus inactive control conditions, lacking the active 
ingredient (e.g., no treatment, wait-list, pill placebo; Higgins & Green, 2011; Meinert, 2012), 
per treatment category (e.g., psychotherapy), including sensitivity analyses for the most 
common treatments. Second, multiple active treatments were directly compared across and 
within treatment categories to evaluate comparative efficacy pre- to post-treatment and/or 
follow-up. Active treatments have an active ingredient intended to produce a treatment effect 
(e.g., different variant of the same intervention, medication, or therapy; Higgins & Green, 
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2011; Meinert, 2012). Third, in order to explain heterogeneity of pooled effects, meta-
regression analysis was conducted to indirectly compare treatment, patient, and method 
characteristics and study quality on primary outcomes at post-treatment (see Hilbert et al., 
2017, and moderation analysis table described below).  
For continuous outcomes, the treatment effect was measured as a standardized mean 
difference between pre-treatment and post-treatment and/or follow-up(s) as well as a mean 
difference for unique scales. Hedge’s g, which corrects for bias given small sample sizes, was 
used as a measure of effect size (0.20, small; 0.50, medium; 0.80, large). Mean and standard 
deviation (SD) were not estimated if only median and interquartile range were provided. 
Large-sample approximations were made for computing sample variance and Wald-type 
confidence intervals were used for outcomes. For categorical outcomes, the treatment effect 
was determined as odds ratios at post-treatment and/or follow-up(s), determined on a 
logarithmic scale and where ½ was added to all cell entries with zero counts (1.44, small; 
2.48, medium; 4.27, large; Borenstein, Hedges, Higgins, & Rothstein, 2009). More than two 
arms from one study within a given treatment category were treated with hierarchical methods 
(Gleser & Olkin, 2009).  
Meta-analyses were conducted if at least two studies provided data. Random effects 
models were computed. The statistic Q and variance τ2 from the random effects model were 
used to assess and test for heterogeneity. Since it was high, comparison with fixed effects 
models as a sensitivity analysis was not deemed feasible. For assessment of reporting biases, 
funnel plots with differences in means on the horizontal axis, and standard error on the 
vertical axis, were inspected. Trim and fill procedures with the R0 estimator (Duval & 
Tweedie, 2000a, 2000b) and the fail-safe N were used to assess reporting bias. The fail-safe N 
indicates how many papers with null results would need to be added for a “small effect size,” 
taken here to be 0.20 for standardized mean differences and 1.5 for odds ratios (Orwin, 1983). 
Standard power analytic methods for random effects models (Hedges & Pigott, 2001) showed 
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that the power for the primary outcomes ranged from 20% for the smaller categories (e.g., 
self-help WLT) to 100% for the larger categories (e.g., psychotherapy). All data were 
analyzed using the “metafor” package of R version 3.4.2 (R Core Team, 2016; Viechtbauer, 
2010). A two-tailed α < .05 was applied to significance testing. 
Quality of Evidence 
 The overall quality of evidence was rated for the primary outcomes according to the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach 
(Schünemann, Brożek, Guyatt, & Oxman, 2013). Internal validity (risk of bias, inconsistency, 
imprecision, publication bias) and external validity (indirectness) were rated for each 
treatment category. Two psychologists (M.Sc. level) conducted the GRADE rating together, 
using evidence profiles, for presentation in a summary of findings table. For unpublished 
studies, because the risk of bias rating was not available, a GRADE rating was not made. 
Results 
Inclusion and Study Characteristics 
 As shown in the PRISMA flow diagram (Figure 1), the literature search yielded 
11,363 articles after removal of duplicates. Following title and abstract screening, 579 full 
texts were screened for eligibility, from which 81 were included in this study (60 studies 
excluded because of ≥ 5 inclusion criteria not fulfilled, Table A1, online supplement; for 
study effect sizes, see Forest plots described below). The 81 studies collated a total of 195 
conditions (study arms). Of these conditions, 138 were active and 57 were inactive conditions. 
A total of 76 studies were published as original articles, 2 studies were published as abstract 
(Yu et al., 2017) or poster (Navia et al., 2017), while 3 studies were unpublished (Hilbert et 
al., Richard et al., Schag et al.). 
 Among the active treatment conditions (Table B1, online supplement), of the 43 
psychotherapy conditions most used CBT, with a few conditions utilizing interpersonal 
psychotherapy, psychodynamic, and humanistic therapies. Fourteen structured self-help 
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conditions, mostly based on CBT, were conducted in a guided or unguided format. 
Pharmacotherapy was evaluated in 30 conditions, including second generation 
antidepressants, central nervous system stimulants, anticonvulsants, and other medications. 
Regarding WLTs, behavioral WLT was utilized in 7 conditions, combining diet, exercise, 
and/or behavioral strategies. Behavioral weight loss guided self-help treatment was utilized in 
3 conditions. Pharmacological WLT was utilized in 5 conditions. For bariatric surgery, no 
RCTs were available. Combined treatment was utilized in 30 conditions, and mostly included 
combinations of CBT, behavioral WLT, and pharmacological interventions. Inpatient 
treatment was used in 6 conditions with a focus on weight loss, or on BED and weight loss. 
Treatment characteristics are described in Table A1, online supplement. 
 Among the inactive control conditions (Table B1, online supplement), most 
psychotherapy and self-help treatment studies used wait-list control, while a few studies used 
no treatment control, attention placebo, or usual care. All pharmacotherapy, pharmacological 
WLT, and combined treatment studies with inactive control conditions utilized pill placebo. 
Inactive control conditions in behavioral or self-help WLT studies were wait-list, attention 
placebo, or usual care. No inactive control conditions were used in inpatient treatment studies. 
Sample Characteristics 
 The included studies encompassed N = 7,515 individuals with BED. Of these, 2,488 
were treated in active conditions and compared with 2,400 patients in inactive control 
conditions. A total of 2,627 patients came from active conditions in RCTs without inactive 
control conditions. Baseline sociodemographic and clinical characteristics are summarized in 
Table C1, online supplement. One study included patients under the age of 18 (Hilbert et al.).  
Pre-treatment to Post-treatment Change versus Inactive Control 
 The meta-analytical pre- to post-treatment results are displayed in Figure 2 (see Table 
D1, online supplement, for detailed results). Regarding primary outcomes, binge-eating 
episodes were significantly reduced with a large pooled effect size by psychotherapy and with 
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medium effect size by self-help treatment, when compared to inactive control conditions, 
mostly wait-list. They were further reduced with small effect sizes by pharmacotherapy and 
pharmacological WLT in comparison to pill placebo (see Forest plot in Figure D1). For 
abstinence from binge eating, the pooled odds ratio was significant in psychotherapy and self-
help treatment, providing large odds ratios of 9.9 or 8.5, respectively, as well as in 
pharmacotherapy and pharmacological WLT with small odds ratios, when compared to the 
abovementioned inactive control conditions (see Forest plot in Figure D2). The effects on 
binge-eating outcome were non-significant in self-help WLT and combined treatment. 
Descriptively, post-treatment rates of abstinence from binge eating were between 45% and 
54% in RCTs with inactive control conditions (psychotherapy 53%, 95% CI 45 to 61%; self-
help-treatment 46%, 95% CI 33 to 59%; pharmacotherapy 45%, 95% CI 40 to 50%; 
pharmacological WLT 54%, 95% CI 44 to 64%; combined treatment 46%, 95% CI 39 to 
54%).  
 Regarding secondary outcomes, eating disorder psychopathology was significantly 
reduced with medium effect size by psychotherapy and self-help treatment when compared to 
inactive control conditions such as wait-list, and with small effect size by combined treatment 
when compared to pill placebo, while effects for pharmacotherapy and pharmacological WLT 
versus pill placebo were non-significant. Depression was significantly reduced with small 
effect size by psychotherapy and combined treatment versus inactive control conditions. Body 
weight was significantly reduced with large effect size in pharmacological WLT (-3.6 kg), 
with medium effect size in combined treatment (-3.6 kg), and with small effect size in 
pharmacotherapy (-2.3 kg), when compared to pill placebo. BMI was significantly reduced 
with small effect sizes in pharmacotherapy and pharmacological WLT when compared to pill 
placebo. All other effects on secondary outcomes were non-significant, or data were 
unavailable (i.e., for self-help WLT).  
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 For patients in active intervention conditions, 24 pharmacotherapy, 3 pharmacological 
weight loss and 4 combined treatment studies reported adverse events. In all, 2,656 events 
were reported in 1,825 patients (586 gastrointestinal upset, 763 sympathetic nervous system 
arousal, 472 sleeping disorders, 267 headache, and 568 miscellaneous events). For patients in 
inactive control conditions, i.e. pill placebo, 22 pharmacotherapy studies and 1 combined 
treatment study reported adverse events. Here, 1,099 events were reported in 1,430 patients 
(223 gastrointestinal upset, 203 sympathetic nervous system arousal, 208 sleeping disorders, 
179 headache, and 286 miscellaneous events). For pharmacotherapy compared to pill placebo, 
the incidence rate ratio for adverse events was 2.1 (95% CI 1.8 to 2.5, p < .001). Because of 
adverse events, 184 patients terminated treatment (10.1%), while 68 patients terminated the 
inactive control intervention (4.8%). A meta-analysis showed an odds ratio of 2.2 (95% CI 1.6 
to 3.1, p < .001) for discontinuing pharmacotherapy versus pill placebo due to adverse events.  
 Compared to inactive control conditions, mainly wait-list, drop-out from treatment 
was significantly increased in psychotherapy and self-help treatment with small odds ratios of 
1.9 or 2.4, respectively. Descriptively, drop-out ranged from 19% to 29% in RCTs with 
inactive control condition (psychotherapy 19%, 95% CI 15 to 23%; self-help treatment 24%, 
95% CI 19 to 31%; pharmacotherapy 29%, 95% CI 25 to 33%; self-help WLT 22%, 95% CI 
8 to 49%; pharmacological WLT 26%, 95% CI 18 to 36%; combined treatment 22%, 95% CI 
18 to 27%). 
 A sensitivity analysis confirmed the results for the most frequently used treatments of 
CBT, CBT self-help treatment, and lisdexamfetamine (Table E1, online supplement). CBT 
self-help treatment showed an additional significant small-size reduction of depression versus 
inactive control conditions, mostly wait-list. Lisdexamfetamine showed significant medium-
size effects on binge-eating episodes and abstinence from binge eating and a large-size effect 
on body weight, but a less than small-size effect on body mass index, when compared to pill 
placebo. 
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 Only a few studies provided data on long-term follow-up effects versus inactive 
control conditions so that meta-analyses were not conducted. 
Pre-treatment to Follow-up Change versus Active Control 
 The direct comparison of treatment categories at post-treatment and follow-ups is 
presented in Figure 3 and Table F1, online supplement. Because of limited data, Table F1 
contains single study results in addition to meta-analytic results in order to complement the 
discussion.  
 Psychotherapy had significantly higher odds for abstinence from binge eating at 3-6-
month follow-up (Peterson et al., 1998, 2009) and lower odds for drop-out than CBT self-help 
treatment (de Zwaan et al., 2017; Peterson et al., 1998, 2009; Wilson et al., 2010), but no 
further short- and long-term differences were found in primary and secondary outcomes. Data 
were unavailable for meta-analytic comparison of psychotherapy versus pharmacotherapy. 
When compared to behavioral WLT, psychotherapy led to significantly lower binge-eating 
episodes and eating disorder psychopathology at post-treatment, and a significantly higher 
abstinence from binge eating at 6-12-month follow-up (2-4 RCTs: Grilo et al., 2011; Munsch 
et al., 2007; Nauta et al., 2000; Wilson et al., 2010). However, psychotherapy resulted in a 
significantly lower BMI loss than behavioral WLT at post-treatment. Psychotherapy did not 
differ from combined treatment (all containing CBT) on either of the primary and secondary 
outcomes across time points, but showed a significantly lower drop-out (2-4 RCTs: Grilo et 
al., 2011; Le Grange et al., 2002; Ricca et al., 2001, 2009). Within the psychotherapies, a 
comparison of CBT versus other psychotherapies, including humanistic therapy, interpersonal 
therapy, and psychodynamic therapy, showed a significantly greater post-treatment reduction 
of binge-eating days in CBT, but no further differences on the primary and secondary 
outcomes emerged across time points (2-3 RCTs: Safer et al.., 2010; Tasca et al., 2006; 
Wilfley et al., 2002).  
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 Data were unavailable for meta-analytic comparisons on self-help treatment versus 
pharmacotherapy, behavioral WLT, self-help WLT, and combined treatment. Comparisons 
within the self-help treatment category found no significant short- and long-term differences 
on the primary and secondary outcomes between CBT guided self-help and CBT unguided 
self-help (2-3 RCTs; Carter & Fairburn, 1998; Peterson et al., 1998, 2009).  
 Pharmacotherapy (fluoxetine, fluvoxamine) yielded a lower reduction of binge-eating 
episodes at post-treatment and 6-12-month follow-up than combined treatment with CBT (2 
RCTs; Grilo et al., 2005c; Ricca et al., 2001). Data were unavailable on comparisons of 
pharmacotherapy with behavioral WLT. Comparing specific medications, fluoxetine did not 
differ from other second generation antidepressants (i.e., fluvoxamine, sertraline) in its effects 
on the primary and secondary outcomes (2 RCTs; Leombruni et al., 2008; Ricca et al., 2001). 
 Behavioral WLT had a significantly higher effect than combined treatment with CBT 
and with or without desipramine on eating disorder psychopathology at 3-6-month follow-up 
(2-3 RCTs: Agras et al., 1994; de Zwaan et al., 2005; Grilo et al., 2011). It also had a lower 
effect on depression and a higher effect on BMI at post-treatment. Data were unavailable on 
comparisons of pharmacological or self-help WLT with combined treatment and on different 
modalities of WLTs. Data were further unavailable for comparisons of different modalities of 
inpatient treatment.  
Moderation Analyses 
 In the meta-regression analyses on moderators of primary outcomes from pre- to post-
treatment (Table G1, online supplement), abstinence from binge eating, but not the reduction 
of binge-eating episodes was significantly higher in group versus individual treatment. Short-
term treatments (< 10 weeks) showed significantly greater effects on binge-eating episodes 
than longer-term treatments (≥ 10 weeks), but no differences were found for abstinence. 
Regarding the mode of recruitment, the primary outcomes did not differ by clinical 
recruitment versus population-based or mixed recruitment.  
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 Patient baseline characteristics were significant moderators of the reduction of binge-
eating episodes, but not of abstinence from binge eating: The lower patients’ age and BMI, 
the higher the proportion of women in the RCT (≥ 90%, the median value), and the higher the 
baseline number of binge-eating episodes, the greater the reduction of binge-eating episodes.  
 Regarding methodology, the primary outcomes were not significantly moderated by 
analytic design (intent-to-treat vs. completer analyses) or time frame of assessment of binge 
eating (4-week vs. 1-week assessment). Regarding the method of assessment, interview-based 
assessment recorded lower improvement of binge-eating episodes than questionnaire or diary-
based assessment. Moderation analyses were not conducted for treatment integrity check, 
therapist training, manualization of treatment, and diagnosis and duration of BED because of 
a lack of data. 
Study Quality 
 The methodological quality across studies varied widely (Table H1, online 
supplement). Across all 76 published RCTs, only 10 (13%) studies were judged as having an 
overall low risk of bias according to the Cochrane criteria, while most studies were 
categorized as unclear (32, 42%) or high (34, 45%) risk of bias. Considering the risk of bias 
per study arm within treatment category (Figure H1), the greatest number of low risk of bias 
ratings was found for self-help treatment and pharmacological interventions, whereas the 
greatest number of high risk of bias ratings were assigned to self-help WLT and inpatient 
treatment. The risk of bias and blinding per se were not significant moderators for the primary 
outcomes (Table G1, online supplement).  
Reporting Biases 
 Funnel plot analyses using trim and fill methods for the primary outcomes documented 
that the estimates were not substantially affected by reporting biases, despite evidence of non-
reporting of studies (Figures I1 to I2). For example, 43 RCTs were available for estimating 
the effect of active intervention versus inactive control on the pre- to post-treatment change of 
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binge-eating episodes. The trim and fill methods indicated that 6 studies are missing (p = 
.0078), which would change the standardized effect size from 0.50 to 0.43. 
Quality of Evidence 
 The overall quality of evidence regarding the primary outcomes from RCTs with an 
inactive control group was very low across treatment categories and low for binge-eating 
episodes in combined treatment studies, as displayed in Figure 4. The main reasons for 
downgrading the quality of evidence were limitations, inconsistency, indirectness, 
imprecision, and publication bias. 
Discussion 
 Over the past decade, the literature on the treatment of BED has more than doubled. 
This meta-analysis confirmed, refined, and extended previous findings of comprehensive 
meta-analyses (Brownley et al., 2016; Ghaderi et al., 2018; Vocks et al., 2010): 
Psychotherapy showed large-size effects in RCTs with inactive control groups, mostly wait-
list control, for the primary outcomes of binge-eating episodes and abstinence from binge 
eating, followed by structured self-help treatment with medium-to-large effects. 
Pharmacotherapy and pharmacological WLT significantly improved binge-eating outcome in 
most RCTs when compared to pill placebo, with small effect sizes, whereas effects of self-
help WLT and combined treatment were non-significant. Across these treatments, post-
treatment abstinence from binge eating ranged from 45% to 54%. In contrast to short-term 
data, there was a lack of data on longer-term efficacy versus inactive control conditions, so 
that a controlled meta-analytical evaluation of the maintenance of therapeutic gains was not 
conducted. For comparative efficacy directly derived from RCTs with active control groups, 
there was little meta-analytical evidence for the superiority of one treatment category or 
specific treatment in the short or long term.  
Efficacy Within Treatment Categories 
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 Regarding psychotherapy, the high efficacy for binge-eating outcome in comparison 
with inactive control conditions such as wait-list is consistent with previous meta-analyses 
(Brownley et al., 2016; Ghaderi et al., 2018; Vocks et al., 2010). As in Vocks et al. (2010), 
medium and small effect sizes with psychotherapy were found for the post-treatment 
improvement of eating disorder psychopathology and depression, respectively; these were 
among the highest across all treatment categories, whereas body weight was not significantly 
reduced when compared to inactive control conditions. Depression and obesity, both 
representing comorbid conditions of BED (Kessler et al., 2013), are usually not within the 
main focus of psychotherapy for BED (e.g., Fairburn, 2008); augmenting the efficacy in these 
parameters awaits further research, for example, through specific interventions (e.g., Grilo, 
Reas, & Mitchell, 2016; Palavras et al., 2017). Notably, the odds of drop-out from treatment 
showed a two-fold increase in psychotherapy (and self-help treatment) when compared to 
inactive control groups, though the rate of 19% was among the lowest. Clinically, the 
significant odds of attrition highlight the relevance of therapeutically fostering and 
maintaining patient motivation in treatment, for example, through motivation-enhancing 
communication strategies and interventions (Dray & Wade, 2012).  
 The majority of psychotherapy trials used CBT, and a sensitivity analysis confirmed 
its efficacy, providing large evidence for this approach (Ghaderi et al., 2018; Linardon, Wade 
et al., 2017). However, there were only a few studies offering comparisons between different 
psychotherapies: A direct comparison with other conceptually and procedurally distinct bona 
fide psychotherapies showed that CBT outperformed other psychotherapies, including 
humanistic therapy, interpersonal psychotherapy, and psychodynamic therapy regarding a 
greater post-treatment reduction of days with binge eating with small effect size. This result is 
in line with Linardon, Wade et al. (2017) who found superiority of CBT versus other active 
psychotherapies on binge-eating outcome. A separate consideration of these other 
psychotherapies, however, demonstrated that CBT (i.e., dialectical behavior therapy) was only 
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superior to humanistic therapy at post-treatment with higher abstinence from binge eating, 
lower depression, and lower attrition in one study (Safer et al., 2010; Table F1, online 
supplement). This treatment had been conceptualized as a credible psychological placebo 
controlling for common factors (e.g., therapeutic alliance; Wampold, 2015), while lacking 
specific ingredients for the treatment of BED (Safer & Hugo, 2006). It was based on its own 
theory, provided a treatment rationale, and utilized non-specific common factor interventions. 
Thus, limited evidence speaks for the specificity of CBT in the treatment of BED when 
compared to non-specific humanistic therapy. Simultaneously, the relevance of common 
factors in the treatment of patients with BED needs to be recognized, as the efficacy of 
humanistic therapy approached that of CBT, which is in line with findings on other mental 
disorders (Wampold, 2015).  
 In contrast, no differences between CBT and other conceptually and procedurally 
distinct bona fide psychotherapies specifically addressing the symptomatology of BED (i.e., 
interpersonal psychotherapy, Wilfley et al., 2002; psychodynamic therapy, Tasca et al., 2006) 
were found (Table F1, online supplement), which is consistent with Spielmans et al.’s (2013) 
meta-analysis and evidence from other mental disorders (Wampold, 2015). Thus, the 
specificity of CBT versus other psychotherapies using other active ingredients to address the 
symptomatology of BED was not shown. This absence of significant differences may be 
attributable to treatment foci on overlapping or equally relevant maintenance factors of binge 
eating, an overlap in the use or similar potency of specific interventions, and/or the 
abovementioned relevance of common factors. Limited evidence makes it currently 
impossible to exactly determine the contribution of these putative factors to the outcome of 
psychotherapies for BED. In a few studies of BED, treatment-specific mediators or 
mechanisms of action have not been identified (Brauhardt, de Zwaan, & Hilbert, 2014; 
Linardon, de la Piedad Garcia et al., 2017), and common factor relationship variables were a 
non-specific predictor of psychotherapy outcome (Brauhardt et al., 2014). Given this limited 
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research on BED and considering evidence from other mental disorders (Wampold, 2015), it 
remains plausible to assume that both specific ingredients and common factors contribute to 
psychotherapy outcome of BED, despite the lack of comparative efficacy in a couple of 
studies in this meta-analysis. Overall, as the comparative efficacy results of CBT versus other 
bona fide psychotherapies were based on a small number of studies only, a definitive 
conclusion that CBT outperforms other psychotherapies does not seem to be justified based 
on this meta-analysis’ results. More research is warranted in order to clarify comparative 
efficacy and identify through which mechanisms psychotherapies, ideally based on validated 
maintenance models, work for patients with BED, for example, through mediator analyses, 
experimental designs, or dismantling studies (Kazdin, 2007). 
 Favorable results were documented for structured self-help treatment, mostly applying 
CBT manuals, with medium-to-large effects on post-treatment binge-eating outcome versus 
inactive control conditions such as wait-list, which is smaller than in the few initial studies 
examined by Vocks et al. (2010). As with psychotherapy, eating disorder psychopathology 
was improved with medium effect size when compared to inactive control conditions, while 
there were no significant effects on body weight consistent with Vocks et al. (2010). No 
significant effects existed for depression either, although its improvement reached 
significance in a sensitivity analysis on CBT self-help treatment, providing additional support 
for the CBT approach (Ghaderi et al., 2018). However, there was not enough evidence for 
direct meta-analytical comparison of different self-help manuals. A direct comparison of self-
help treatment in guided versus unguided format, all based on CBT, did not reveal any 
differences on the primary outcomes in a low number of RCTs, which is consistent with a 
previous meta-regression analysis indirectly comparing self-help treatments for BED and 
bulimia nervosa (Beintner et al., 2014). Although our results permit speculation that in BED 
guidance may not be indispensable for a favorable binge-eating outcome, optimal levels and 
types of guidance still need further clarification (Wilson & Zandberg, 2012). Significantly 
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elevated odds for drop-out from self-help treatment were observed in 24% of patients, which 
is consistent with the literature (Beintner et al., 2014), and advocates for measures to improve 
adherence, for example, with guidance by a mental health specialist.  
 For pharmacotherapy, as in previous meta-analyses (Brownley et al., 2016; Ghaderi et 
al., 2018; Vocks et al., 2010), the majority of pharmacological agents were second generation 
antidepressants whereas more recently, the central nervous stimulant lisdexamfetamine has 
been evaluated, approved by the US Food and Drug Administration in 2015 as the only drug 
with an indication for the treatment of BED. Pharmacotherapy outperformed pill placebo in 
most RCTs, showing small effects on binge-eating outcome compared to pill placebo and a 
small-size weight loss effect, while eating disorder psychopathology and depression were not 
significantly improved. A sensitivity analysis for lisdexamfetamine confirmed the 
significance of weight-related effects and additionally documented significant medium-size 
effects on binge-eating outcome, which is consistent with previous meta-analytic results 
(Ghaderi et al., 2018). The results are further consistent with meta-analyses showing greater 
abstinence from binge eating after treatment with lisdexamfetamine and second-generation 
antidepressants than with placebo in RCTs, while results on weight loss depression, and 
eating disorder psychopathology were heterogeneous (Brownley et al., 2016; Fornaro et al., 
2016; Ghaderi et al., 2018). Only a few studies on second-generation antidepressants 
compared specific medications, without showing any differential effects. Overall, attrition 
rates for pharmacotherapy were 29%, but were not significantly increased when compared to 
pill placebo. However, the incidence rate of adverse events and the related odds of premature 
discontinuation were significant and amounted to roughly 2 in pharmacotherapy, consistent 
with previous meta-analytical evidence (Fornaro et al., 2016), which requires - together with 
the substantial attrition rate - careful consideration in the treatment of patients with BED. Of 
note, pharmacotherapy trials (and several combined treatment trials) were the only studies to 
systematically provide data on adverse events. Further adequately powered efficacy trials are 
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needed in order to discern mechanisms of action of different agents and establish optimal 
doses and administration specifics (Reas & Grilo, 2015). Agents efficacious in the treatment 
of comorbid mental disorders, such as attention-deficit/hyperactivity disorder or substance use 
disorder, as well as obesity are promising candidates for future pharmacotherapy evaluations 
in patients with BED (McElroy, 2017; Reas & Grilo, 2015). 
 Regarding treatments offering a combination of interventions, this meta-analysis 
newly documented, in a small number of RCTs with inactive control groups, non-significant 
effects on binge-eating outcome versus pill placebo, but significant small-size improvements 
of eating disorder psychopathology and depression in addition to a medium-size weight loss 
effect. Due to the heterogeneity of combined treatments, the low number of study arms, and 
various control conditions, however, it was not possible to compare different combination 
treatments versus inactive control conditions or against each other.  
 As in previous meta-analyses (Ghaderi et al., 2018; Vocks et al., 2010), RCTs 
comparing behavioral WLT with inactive control conditions in patients with BED were 
lacking, so that the efficacy of this standard obesity treatment approach could not be meta-
analytically determined for BED. Regarding further WLTs in comparisons with diverse 
inactive control conditions in RCTs, a few studies did not show that self-help WLT 
significantly improved binge-eating outcome. Data on other outcomes were not sufficient for 
meta-analysis. Pharmacological WLT significantly improved binge-eating outcome at post-
treatment with small effects and weight loss with large effect when compared to pill placebo. 
However, effects were non-significant for eating disorder psychopathology and depression. 
Of note, pharmacological WLT studies used sibutramine or d-fenfluramine, and both were 
withdrawn from the market in many countries for the treatment of obesity because of a risk of 
major cardiovascular events. Studies offering other currently licensed anti-obesity 
medications in patients with BED such as orlistat were not contained in pharmacological 
WLT trials (but in 3 arms of combined treatment). Further, this study searched for surgical 
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WLT being increasingly applied to patients with BED (Meany, Conceição, & Mitchell, 2014), 
but did not locate any RCT, likely related to the fact that randomization is ethically difficult in 
the surgical treatment approach.  
 Unlike the other treatment categories, inpatient treatments do not represent a 
conceptually distinct approach to treatment, but rather an intensive form of combined 
treatment with a focus on weight loss, or on BED and weight loss, in an inpatient setting. 
Although a few RCTs on inpatient treatment were retrieved, comparisons with inactive 
control conditions were unavailable, and data on different modalities were insufficient, so that 
the efficacy of inpatient treatment for patients with BED was not evaluated. 
Comparative Efficacy Across Treatment Categories 
 Overall, from direct comparisons there was little evidence for the superiority of one 
treatment category. Psychotherapy led to higher follow-up rates of abstinence from binge 
eating and lower drop-out than CBT self-help treatment in a low number of RCTs, which is 
consistent with narrative review (Peat et al., 2017), suggesting a higher efficacy of 
psychotherapy which is commonly offered with greater intensity and higher level of guidance 
by a therapist. The comparative efficacy of psychotherapy versus pharmacotherapy was 
addressed by one study only, demonstrating superiority of CBT in reducing binge-eating 
episodes at post-treatment and follow-up and BMI at follow-up when compared to second-
generation antidepressants (Ricca et al., 2001; Table F1, online supplement). Based on this 
single study, a definitive conclusion for the comparison of psychotherapy or CBT versus 
pharmacotherapy cannot be drawn. In contrast, psychotherapy revealed greater short- and 
long-term efficacy for binge-eating outcome than behavioral WLT in several RCTs, which 
confirms meta-regression and systematic review results (Peat et al., 2017; Vocks et al., 2010). 
While psychotherapy was more efficacious than behavioral WLT in the short term for 
improving eating disorder psychopathology, it had lower effects on BMI. Grilo et al. (2011) 
additionally documented a greater abstinence from binge eating in psychotherapy (CBT), but 
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no differences on BMI at follow-up (Table F1). These results are consistent with a systematic 
review (Peat et al., 2017) and suggest that psychotherapy outperforms behavioral WLT on 
BED symptomatology, but has lower effect on BMI, presumably in the short term only. These 
effects may be attributable to differences in treatment foci (BED versus obesity) and related 
interventions within these treatments (Palavras et al., 2017). Possibly related to the 
documented high efficacy of psychotherapy, there were no differential effects of 
psychotherapy versus combined treatment in several RCTs, except for a lower drop-out from 
treatment. In contrast, pharmacotherapy yielded a lower improvement of binge-eating 
episodes than combined treatment at both post-treatment and follow-up. In addition, there was 
single study support (Grilo et al., 2005c; Table F1) for the superiority of combined treatment 
on abstinence from binge eating and eating disorder psychopathology in the short and long 
term as well as depression in the short term, but a lower longer-term effect on BMI, which is 
consistent with a narrative review (Grilo et al., 2016). Very little evidence was available for 
comparisons among the categories of self-help treatment, pharmacotherapy, behavioral WLT, 
and combined treatment, and no evidence was available for inpatient treatment.  
Moderation Analyses 
 Meta-regression analyses based on indirect comparisons served to elucidate influences 
of treatment, patient, and methodological characteristics on the primary outcomes at post-
treatment. The superiority of group versus individual treatment format for binge-eating 
outcome may be related to the fact that the majority of psychotherapy studies with high 
efficacy for the primary outcomes were conducted in a group format. Shorter duration of 
treatment may be less suited for the treatment of BED than longer duration because of high 
symptomatic burden, for example, as reflected in the high number of binge-eating episodes at 
baseline or long duration of BED. Clinical versus population-based or mixed recruitment did 
not moderate primary outcomes, suggesting a similar symptom profile of patients across 
treatment settings and recruitment avenues.  
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 Regarding patient characteristics, the fact that lower baseline age and BMI, higher 
proportion of women, and higher number of binge-eating episodes significantly predicted a 
greater post-treatment reduction of binge-eating episodes, is unlikely to reflect matching of 
patients with these characteristics into treatments with higher efficacy (Table C1, online 
supplement), although combinations of moderators, for example, interactions with treatment 
category, were not considered because of potential interrelations among variables. Rather, 
lower age and BMI may reflect a lower chronicity of BED. A higher proportion of women 
may indicate a greater compliance with treatment regimens. Higher baseline binge-eating 
episodes may allow for larger changes to occur. More research is warranted to further clarify 
the inconclusive evidence on patient characteristics as treatment moderators (Linardon, de la 
Piedad Garcia et al., 2017).  
 Regarding methodology, no moderating effect on primary outcomes was found for: the 
use of intent-to-treat analyses versus completer analyses and time frame of assessment of 
binge eating over the last 1 week versus 4 weeks. Interview-based assessment was associated 
with lower improvement of binge-eating episodes compared to questionnaire or diary-based 
assessment, suggesting an overestimation of therapeutic effects by self-report. Further 
moderation analyses were not conducted because of a lack of data. 
Limitations of Included Studies 
 Regarding the risk of bias, study quality was heterogeneous. The most common 
problem, beyond a lack of blinding of participants and/or personnel, which is hardly feasible 
in psychological treatment studies, was a bias through confounding variables that were not 
sufficiently considered. In addition, a low risk of bias for blinding of outcome assessors, 
attrition bias, and reporting incomplete outcome data, was found in only a minority of studies. 
The lowest overall risk of bias was found in pharmacological treatment studies. Of note is that 
moderation analysis did not reveal any difference on the primary outcomes by risk of bias or 
blinding. Despite evidence for data censoring, it was not likely to impact outcomes 
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meaningfully. These results indicate that an unclear or high risk of bias does not lead to an 
overestimation of treatment efficacy regarding the primary outcomes. Given the multiple risks 
of bias assigned to many treatment studies, future clinical studies are nevertheless 
recommended to systematically consider risk of bias potential at the time of study planning. 
 Further study limitations pertained to the heterogeneous reporting of sample 
characteristics, making equity-relevant comparisons according to the PROGRESS framework 
impossible. While in most studies female patients were overrepresented, presumably because 
of gender-specific health care-seeking, many studies restricted the inclusion to patients in a 
specific age or BMI range. Only one RCT on an adolescent population fulfilled the inclusion 
criteria (Hilbert et al.). In general, future research should specifically target or not exclude 
underrepresented groups for better generalization of treatment effects. Finally, especially for 
pharmacotherapy, it is notable that many studies applied restrictive exclusion criteria 
regarding mental or medical comorbidities and were conducted by one research team only, 
which makes the generalization of effects challenging and underlines the necessity to examine 
diverse, clinically heterogeneous populations with BED. Regarding outcome assessments, it 
was surprising that remission from BED and quality of life, two core clinical outcome criteria, 
were assessed in a minority of studies only, so that the results were not included in this report. 
Strengths and Limitations of the Meta-Analysis 
 Strengths of this study are the provision of a comprehensive meta-analysis on the 
efficacy of psychological and medical treatments for BED, allowing for high generalizability 
to clinical practice. Current guidelines for protocol development, reporting, and quality 
evaluation were followed (see Hilbert et al., 2017), including the Meta-Analysis Reporting 
Standards (MARS; American Psychological Association, 2008). The broad search, screening, 
and data extraction, based on a standardized coding scheme, were performed by two scientists 
independently. Interrater agreement of coding was almost perfect. A new search for the total 
publication time period was carried out because of increased quality standards for meta-
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analyses. A very high interstudy reliability with Vocks et al. (2010) for studies published up 
to June 2006 was found, lending additional support to reliability. In contrast to Vocks et al. 
(2010) and to the study protocol (Hilbert et al., 2017), unpublished studies were included in 
order to limit publication bias, while non-randomized controlled studies and uncontrolled 
studies and the analysis of within-condition results were omitted from this meta-analysis in 
order to rule out confounding through time and assessment effects. We examined a broad 
range of clinically relevant primary and secondary outcome variables that were derived from 
assessments that varied across studies, which speaks for generalizability, although specific 
psychometric properties were not provided because of the variation of measures across 
studies. Single treatments were grouped into broader treatment categories (Table A1, online 
supplement), making variations within treatment categories likely. Direct comparisons from 
RCTs were examined for establishing comparative efficacy, while indirect comparisons 
served to identify moderators of treatment only.  
 Limitations are that study language was restricted to English and economic aspects 
were not considered. The power for determining effects on binge-eating outcome ranged from 
low for the small treatment categories to excellent for the large treatment categories. Because 
of a limited database, caution is required, especially when interpreting the results on the 
smaller treatment categories, pre-treatment to follow-up change, comparative efficacy, and 
moderation analyses. Regarding study quality, although it may seem to be a limitation that we 
did not exclude studies with high risk of bias, risk of bias was not found to be a moderator of 
treatment outcome.  
Clinical and Research Implications 
 In this meta-analysis, informing the renewal of the German evidence-based clinical 
guideline for BED (AWMF, 2010), the overall quality of evidence for the main outcomes was 
rated to be low to very low across treatment categories for various GRADE factors 
(Schünemann, Brożek, Guyatt, & Oxman, 2013), which is consistent with the NICE eating 
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disorder guideline (2017). With this low overall quality in mind, this study underlined a high 
efficacy of psychotherapy, especially CBT, and self-help treatment for binge-eating outcome. 
These effects have to be weighed against a lack of data on adverse events and high drop-out 
rate particularly in self-help treatment. While this meta-analysis’ results overall confirm self-
help treatment, especially if based on CBT, as efficacious, its potentially lower longer-term 
efficacy and higher drop-out rate support its use if psychotherapy is not available (e.g., during 
waiting periods) or not acceptable. Of note is that self-help treatment was found to be less 
costly, however, not necessarily more cost-effective than psychotherapy (König et al., 2018). 
Evaluating stepped care models, with self-help treatment as a first step and psychotherapy as a 
second step would allow to provide an evidence base to the respective recommendation of the 
NICE guidelines (2017) and permit addressing the increased discontinuation from self-help 
treatment (Tasca et al., 2018). In both treatment categories, the specificity of effects in 
comparison to placebo, for example, psychological placebo (cf. Safer & Hugo, 2006), and in 
comparison to other active treatments awaits further study. 
 Pharmacotherapy was found to be efficacious with small-size advantages over pill 
placebo, while lisdexamfetamine showed a medium-size effect on binge eating. These mostly 
small effects raise questions regarding effective agents and clinical trial design, while the 
placebo response documented in this meta-analysis is consistent with previous research 
demonstrating a substantial, but similar placebo response in BED as in other mental disorders 
(Blom et al., 2014). While the specificity of pharmacological agents in relation to pill placebo 
has generally been documented, only few studies compared different medications, without 
documenting specificity with regard to other pharmacological agents, which represents an 
important area of further research. Overall, pharmacotherapy effects have to be weighed 
against a complete lack of data on long-term administration, increased risk for adverse events, 
and related premature attrition from treatment. 
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 Methodologically, it is important to note that pill placebo conditions commonly used 
in pharmacological RCTs, especially in double-blind designs, are more rigorous than wait-list 
control conditions commonly used in psychological treatment RCTs, as they control not only 
for time and assessment effects, but also for expectancy and demand characteristics. Thus, the 
effect sizes of pill-placebo-controlled pharmacological versus wait-list-controlled 
psychological trials are not comparable. Pill placebo conditions are further not comparable to 
psychological placebo conditions, as used in Safer et al. (2010), that sought to control for 
expectancy and demand characteristics: If not unblinded, for example, through side effects of 
the active medication, pill placebo is in double-blind RCTs indistinguishable from the active 
treatment to patients, therapists, and assessors, leading to the lowered risk of bias described 
above. Because of the placebo effect that substantially influences expectations and learning, 
based on a patient’s psychobiological responses to the treatment context (Ashar, Chang, & 
Wager, 2017), pill placebo, albeit lacking an active ingredient, is more similar to active 
control conditions than to other inactive control conditions such as wait-list or no treatment. 
In future research, other designs and forms of pill placebo may be used in order to disentangle 
or control the placebo effect, for example, active placebos, mimicking side effects of the 
active medication, thereby decreasing the probability of unblinding (Ashar et al., 2017; 
Jensen, Bielefeldt, & Hróbjartsson, 2017). A clarification of the psychobiological mechanisms 
underlying the placebo effect in BED could help to maximize the efficacy of diverse medical 
and psychological treatment approaches for this disorder.  
 Clinically, because of its higher short- and long-term efficacy for the treatment of 
binge eating, psychotherapy may be prioritized over behavioral WLT. Because of its higher 
longer-term effect on binge-eating outcome and lower drop-out, psychotherapy may be 
prioritized over self-help treatment if both treatments are available. As combinations of 
psychotherapy with behavioral WLT and/or pharmacotherapy have not been found to have 
any short- or long-term additive effect on primary or secondary outcomes, they may not be 
Meta-analysis of treatments for binge-eating disorder 33 
prioritized over psychotherapy alone. More high quality research on these and other 
psychological and medical treatments for BED is warranted, with a focus on the long-term 
maintenance of therapeutic gains, comparative efficacy, mechanisms through which 
treatments work, and complex models of care. 
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Figure Captions 
 
Figure 1. Flow diagram of included studies according to “Preferred reporting items for 
systematic review and meta-analysis protocols” (PRISMA-P).  
 
Figure 2. Pre-treatment to post-treatment change per treatment category versus inactive 
control. Black dots indicate significance (p < .05), white dots indicate non-significance (p ≥ 
.05).  
 
Figure 3. Pre-treatment to follow-up change versus active control across and within treatment 
categories. WLT indicates weight loss treatment, CBT indicates cognitive-behavioral therapy. 
Black dots indicate significance (p < .05), white dots indicate non-significance (p ≥ .05). 
aDays with binge eating. 
 





Records identified through database 
searching 























n Additional records identified 
through other sources 
(n = 7) 
Records after duplicates removed 
(n = 11,363) 
Records screened 
(n = 11,363) 
Records excluded 
(n = 10,784) 
Full-text articles assessed 
for eligibility 
(n = 579) 
Full-text articles excluded 
(n = 498) 
- no BED (DSM-5, DSM-
IV) n = 190 
- no BED outcome n = 110 
- no original study n = 78 
- no separate data n = 39 
- no RCT n = 36 
- sample size < 10 n = 22 
- no pre-post data n = 13 
- not in English n = 10 
      
Studies included in 
quantitative synthesis 
(meta-analysis) 























































































−1 0 1Hedge's g, odds ratio




















































 other second-generation antidepressants
CBT guided self-help treatment vs.



























































Hedge's g, odds ratio
Patient or population: Adults with binge-eating disorder 
Settings: Outpatient and inpatient settings 
Intervention: Psychological and medical treatments 
Comparison: Inactive control group in randomized-controlled trials 
 
Outcomes by treatment category Control Intervention Relative effect
(mean diffe-
rence or odds 
ratio) 






Psychotherapy       
Binge-eating episodes 0.18 1.11 0.83 11/672 a  
Abstinence from binge eating 0.13 0.60 9.9 10/667 b  
Self-help treatment       
Binge-eating episodes 0.50 1.26 0.72 7/461 a  
Abstinence from binge eating 0.08 0.44 8.9 5/422 b  
Pharmacotherapy       
Binge-eating episodes 1.62 1.92 0.46 16/1534 c  
Abstinence from binge eating 0.27 0.44 2.0 22/2495 c  
Pharmacological weight loss treatment      
Binge-eating episodes 1.08 2.15 0.47 3/354 b  
Abstinence from binge eating 0.37 0.56 2.2 4/424 c  
Self-help weight loss treatment       
Binge-eating episodes 0.72 0.91 0.36 2/75 b  
Abstinence from binge eating     - only 1 study available 
Combined treatment       
Binge-eating episodes 0.94 1.23 0.26 4/485 d  
Abstinence from binge eating 0.31 0.45 1.8 5/356 d  
adowngraded by three levels due to limitations, inconsistency, indirectness, and imprecision 
bdowngraded by three levels due to limitations, indirectness, and imprecision 
cdowngraded by three levels due to limitations, indirectness, imprecision, and publication bias 
ddowngraded by three levels due to indirectness and imprecision 
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Table A1 







N nse ttreat Control nc Format Outcomes  Time 
points 
Psychotherapy            
Agras et al. (1995) Agras (1995) CBT  CBT 39 12 12 Wait-list 11 Group ABS, EDP, DE, BW  pre, post 








Allen & Craighead 
(1999) 
Allen (1999) Appetite awareness 
training 
CBT 15 8 8 Wait-list 14 Group OBE, ABS, EDP, 
DE 
pre, post 
Brambilla et al. 
(2009) 
Brambilla 
(2009) CBT  
CBT CBT 10 24 24 Active  Group OBE, BW, BMI pre, post 




CBT CBT 86 16 20 Active  Individual OBEd pre, post 
















N nse ttreat Control nc Format Outcomes  Time 
points 




CBT CBT 13 6 3 Active  Individual OBE, ABS, EDP  pre, post 





CBT with virtual 
reality cue exposure 
training 
CBT 16 6 3 Active  Individual OBE, ABS, EDP  pre, post 
Gorin et al. (2003) Gorin (2003) 
CBT 
CBT CBT 32 12 12 Wait-list, 
active 
31 Group OBE, ABS, EDP, 
DE, BMI, DO 
pre, post, 
6m 
Gorin et al. (2003) Gorin (2003) 
CBT-spouse 
CBT with spouse 
involvement 
CBT 31 12 12 Wait-list, 
active 




Grilo et al. (2011) Grilo (2011) 
CBT  
CBT CBT 45a 24 16 Active  Group OBE, ABS, EDP, 
DE, BW, BMI 
pre, post, 
6m, 12m 
Hilbert et al. 
(DRKS00000542) 
Hilbert et al. CBT CBT 29a 20 16 Wait-list 32 Individual OBE, ABS pre, post  
Hilbert & Tuschen- Hilbert (2004) CBT with body CBT 14 30 19.6 Active  Group OBE, ABS, REM, pre, post, 








N nse ttreat Control nc Format Outcomes  Time 
points 





CBT with cognitive 
body image 
intervention 
CBT 14 30 18.6 Active  Group OBE, ABS, REM, 
EDP, DE, BMI 
pre, post, 
4m 






CBT 35 9 9 Wait-list, 
active 
31 Group REM pre, post 







Other 31 9 9 Wait-list, 
active 
31 Group REM pre, post 




CBT CBT 22a 12 12 Active  Group OBE, REM, EDP, 
DE, BMI, DO 
pre, post, 
12m 
Lewer et al. (2017) Lewer (2017) Body image therapy CBT 15 10 10 Wait-list 21 Group OBE, EDP, DE, 
BMI 
pre, post 
Munsch et al. Munsch CBT CBT 44a 16 10.77 Active  Group OBE, OBEd, ABS, pre, post, 








N nse ttreat Control nc Format Outcomes  Time 
points 
(2007); Munsch, 
Meyer, & Biedert 
(2012) 
(2007) CBT REM, EDP, DE, 
QOL, BMI, DO 
72m 
Nauta et al. (2000);  




Cognitive therapy CBT 21a 15 15 Active  Group OBEd, ABS, REM, 
EDP, DE, BW, DO 
pre, post, 
6m, 12m 




CBT CBT 29 17 16 Active  Group OBEd, ABS, DE pre, post, 
6m, 12m 





CBT + maintenance CBT 28 43 28 Active  Group OBEd, ABS, DE pre, post, 
6m 
Peterson et al. 
(1998), Peterson et 
al. (2001) 
Peterson 
(1998) CBT  
CBT CBT 16a 8 14 Wait-list, 
active 
 11 Group OBE, ABS, REM, 












N nse ttreat Control nc Format Outcomes  Time 
points 




CBT CBT 60a 20 15 Wait-list, 
active 
69 Group OBE, OBEd, ABS, 












Preuss et al. (2017) Preuss (2017) 
CBT 




Ricca et al. (2009) Ricca (2009) 
CBT  
CBT CBT 24a 24 22 Active  Individual OBE, BMI pre, post, 
12m 
Ricca et al. (2010) Ricca (2010) 
individual 
CBT 
CBT CBT 72a 24 22 Active  Individual REM pre, post, 
36m 
Ricca et al. (2010) Ricca (2010) 
group CBT 
CBT CBT 72a 22 20 Active  Group REM pre, post, 
36m 








N nse ttreat Control nc Format Outcomes  Time 
points 
Ricca et al. (2001) Ricca (2001) 
CBT 
CBT CBT 20 24 22 Active  Individual OBE, BMI, DO pre, post, 
6m 
Richard et al. 
(ACTRN12614000
894695) 
Richard et al. Eye movement 
desensitization 
reprocessing 
EMDR 16a 10 10 Wait-list 22 Individual OBE, OBEd, EDP, 
DE, BMI  
pre, post 
Safer et al. (2010) Safer (2010) 
DBT 
DBT CBT 50a 21 20 Active  Group ABS, EDP, DE, 
BW, BMI, DO 
pre, post, 
12m 




Humanistic 51a 21 20 Active  Group ABS, EDP, DE, 
BW, BMI, DO 
pre, post, 
12m 
Schag et al. 
(DRKS00007689) 
Schag et al. Impulsivity-focused 
CBT 
CBT 41a 8 8 No 
treatment 








48 16 12.35 Wait-list, 
active 
40 Group OBEd, ABS, EDP, 
DE, BMI, DO 
pre, post, 
6m, 12m 
Tasca et al. (2006) Tasca (2006) CBT CBT 47 16 11.77 Wait-list, 40 Group OBEd, ABS, EDP, pre, post, 








N nse ttreat Control nc Format Outcomes  Time 
points 
CBT active DE, BMI, DO 6m, 12m 
Telch, Agras, & 
Linehan (2001) 
Telch (2001)  DBT CBT 22 20 20 Wait-listb 22 Group OBE, OBEd, ABS, 
EDP, DE, BW 
pre, post, 
3m, 6m 






69a 11 16 Wait-list 70 Individual OBE, ABS, EDP, 








CBT CBT 81a 20 16.6 Active  Group + 
Individual 








IPT IPT 81a 20 17.7 Active  Group + 
Individual 




Wilson et al. (2010) Wilson (2010) 
IPT 





Yu et al. (2017) Yu (2017) CBT face-to-face CBT 9 12 12 Active  Individual OBE, EDP, BW, pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 
CBT face BMI 
Yu et al. (2017) Yu (2017) 
CBT web 
CBT web-based CBT 8 12 12 Active  Individual OBE, EDP, BW, 
BMI 
pre, post 
Self-help treatment            





Unguided self-help CBT 
unguided 
self-help 
24a  12 (Wait-
list)c, 
active 









Guided self-help CBT guided 
self-help 
24a 7 12 (Wait-
list)c, 
Active 













84 16 18 Active  Individual OBEd pre, post 
Duarte et al. (2017) Duarte (2017) Compassionate- Other 17  4 Wait-list 16 Group + OBE, EDP, DE, pre, post, 














Individual BMI 1m 









37a 6 12 Attention-
placebo, 
active 
15 Individual OBE, ABS, EDP, 
DE, BMI 
pre, post 
Grilo, White et al. 
(2013b) 
Grilo (2013b) CBT self-help CBT 
unguided 
self-help 
24  16 Usual 
care 
24 Individual OBE, ABS, EDP, 
DE, BMI, DO 
pre, post 











15a  3 Wait-list, 
active 
13 Individual OBE, OBEd, EDP, 
DE, BMI, DO 
pre, post 




CBT self-help CBT 
unguided 
13a  3 Wait-list, 
active 
13 Individual OBE, OBEd, EDP, 
DE, BMI,DO 
pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 
self-help self-help 























15a 14 8 Wait-list, 
active 
11 Group OBE, ABS, REM, 









CBT partial self-help CBT guided 
self-help 
19a 14 8 Wait-list, 
active 
11 Group OBE, ABS, REM, 
EDP, DE, BMI 
pre, post 






CBT self-help CBT 
unguided 
self-help 
67a 15 20 Wait-list, 
active 
69 Group OBE, OBEd, ABS, 












N nse ttreat Control nc Format Outcomes  Time 
points 









63a 15 20 Wait-list, 
active 
69 Group OBE, OBEd, ABS, 
















Pharmacotherapy            




30a  6 Placebo 30  OBE, ABS, DE, 
BW, BMI, ADV, 
DO 
pre, post 





Chromium high dose Other 8  24 Placebo 30  OBE, ADV, DO pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 







Other 9  24 Placebo 30  OBE, ADV, DO pre, post 
Grilo, Masheb, & 
Wilson (2005c); 







27a  16 Active, 
placebo 












21a  12 Placebo 23  OBE, OBEd, ABS, 
EDP, DE, BW, 
BMI, ADV, DO 
pre, post 






26a  16 Placebo 25  OBE, OBEd, ABS, 
EDP, DE, BW, 
BMI, ADV, DO 
pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 








20a  12 Placebo 20  OBE, OBEd, ABS, 
EDP, DE, BW, 
BMI, ADV, DO 
pre, post 








25a  12 Placebo 25  OBE, OBEd, ABS, 
EDP, ADV, DO 
pre, post 








42a  9 Placebo 43  ABS, ADV, DO pre, post 






20  24 Active   OBE, ABS, EDP, 
DE, BW, BMI 
pre, post 





















22  24 Active   OBE, ABS, EDP, 
DE, BW, BMI 
pre, post 








18a  6 Placebo 16  OBE, ABS, ADV, 
DO 
pre, post 
McElroy, Arnold et 





30a  14 Placebo 31  ABS, ADV, DO pre, post 
McElroy, Hudson et 





19a  6 Placebo 19  OBE, OBEd, ABS, 
EDP, DE, BW, 
pre, post 












BMI, ADV, DO 


















20a  10 Placebo 20  ABS, ADV, DO pre, post 
McElroy, Hudson et 







 16 Placebo 199  OBE, OBEd, ABS, 
BMI, ADV, DO 
pre, post 




Acamprosate Other 20a  10 Placebo 20  OBE, OBEd, ABS, 
EDP, DE, QOL, 
BW, BMI, ADV, 
DO 
pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 




ALKS-33 Other 32a  6 Placebo 37  OBE, OBEd, ABS, 
BW, ADV, DO 
pre, post 
McElroy, 




Armodafinil Other 30a  10 Placebo 30  OBE, OBEd, ABS, 














 12 Placebo 191  ABS, ADV, DO pre, post 
McElroy, Hudson, 
Ferreira-Cornwell 










 12 Placebo 195  ABS, ADV, DO pre, post 
McElroy, Hudson, McElroy Lisdexamfetamine Central 66a  11 Active, 64  OBE, OBEd, ABS, pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 
Mitchell et al. 
(2015c) 
(2015c) 30mg 30mg nervous 
system 
stimulants 
Placebo BW, ADV, DO 
McElroy, Hudson, 










65a  11 Active, 
placebo 
64  OBE, OBEd, ABS, 
BW, ADV, DO 
pre, post 
McElroy, Hudson, 










65a  11 Active, 
placebo 
64  OBE, OBEd, ABS, 
BW, ADV, DO 
pre, post 
Navia et al. (2017) Navia (2017) Dasotraline Other  159 
a 
 12 Placebo 160  OBE, OBEd, ABS, 
EDP, BW, BMI, 
ADV, DO 
pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 








9  12 Placebo 11  OBEd, ABS, EDP, 
DE, BW, ADV, DO 
pre, post 




















White & Grilo 
(2013) 
White (2013) Bupropion Second 
generation 
31a  8 Placebo 30  OBE, ABS, EDP, 
DE, BMI, ADV, 
pre, post 













Behavioral weight loss treatment          








37 30 36 Active  Group ABS, EDP, DE, 
BW, ADV, DO 
pre, post, 
12m 




















45a 16 24 Active  Group OBE, ABS, EDP, 
DE, BW, BMI 
pre, post, 
6m, 12m 








N nse ttreat Control nc Format Outcomes  Time 
points 
strategies 
Levine, Marcus, & 
Moulton (1996) 
Levine (1996) Exercise Exercise 44  24 Wait-list 33 Individual ABS, DE, BW pre, post 
Munsch et al. 
(2007); Munsch, 










36a 10.75 16 Active  Group OBE, OBEd, ABS, 
REM, EDP, DE, 
QOL, BMI, DO 
pre, post 
Nauta et al. (2000); 








16a 15 15 Active  Group OBEd, ABS, REM, 
EDP, DE, BW 
pre, post, 
6m, 12m 



















N nse ttreat Control nc Format Outcomes  Time 
points 
Self-help weight loss treatment           
Barnes et al. (2017) Barnes (2017) 
MI 
Behavioral weight 







8 5 12 Usual 
care, 
active 
8 Individual OBE, OBEd  pre, post, 
3m, 12m 
Barnes et al. (2017) Barnes (2017) 
NP 
Behavioral weight 







7 5 12 Usual 
care, 
active 
8 Individual OBE, OBEd pre, post, 
3m, 12m 










38a 6 12 Attention-
placebo, 
active 
15 Individual OBE, ABS, EDP, 
DE, BMI 
pre, post 
Pharmacological weight loss treatment          








N nse ttreat Control nc Format Outcomes  Time 
points 






30a  12 Placebo 30  OBEd, ABS, EDP, 
DE, BW, ADV, DO 
pre, post 




26a  16 Active, 
placebo 
27  OBE, ABS, EDP, 
DE, BW, BMI,  
pre, post, 
6m, 12m 
Milano et al. (2005) Milano (2005) Sibutramine Anti-obesity 
medication 
10  12 Placebo 10  OBEd, EDP, ADV pre, post 










Wilfley et al. 
(2008) 




 24 Placebo 152  OBE, OBEd, ABS, 
EDP, QOL, BW, 
BMI, DO 
pre, post 
Combined treatment           
Agras et al. (1994) Agras (1994) 
CBT + WLT 




36 30 36 Active  Group ABS, EDP, DE, 
BW, ADV, DO 
pre, post, 
12m 








N nse ttreat Control nc Format Outcomes  Time 
points 
Agras et al. (1994) Agras (1994) 
CBT + WLT + 
desipramine 






36 21 36 Active  Group  ABS, EDP, DE, 
BW, ADV, DO 
pre, post, 
12m 
Brambilla et al. 
(2009) 
Brambilla 










10 24 24 Active  Group  OBE, EDP, BW, 
BMI 
pre, post 
Brambilla et al. 
(2009) 
Brambilla 
(2009) CBT + 
WLT + 
sertraline 





10 24 24 Active  Group  OBE, BW, BMI pre, post 




54  16 Active   Individual OBEd, ABS, REM, 
DE, DO 
pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 
interviewing self-help + 
motivational 
interview  
Devlin et al. (2005) Devlin (2005) 
CBT + WLT + 
fluoxetine 
Behavioral weight 





28a 10.9 +  
13.6 
20 Active  Group + 
individual 
OBE, EDP, DE, 
BW, DO 
pre, post 
Devlin et al. (2005) Devlin (2005) 
CBT + WLT + 
placebo 
Behavioral weight 





25a 10.7 + 
12.4 
20 Active  Group + 
individual 
OBE, EDP, DE, 
BW 
pre, post 




control + fluoxetine 
WLT + 
medication 
32a 10.5  20 Active  Group OBE, EDP, DE, 
BW 
pre, post 
Devlin et al. (2005) Devlin (2005) 
WLT + 
Behavioral weight 
control + placebo 
WLT + 
placebo 
31a 8.8 20 Active  Group OBE, EDP, DE, 
BW 
pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 
placebo 
de Zwaan et al. 
(2005) 
de Zwaan 
(2005) CBT + 
WLT 













44a  24 Placebo   Individual REM, EDP, DE, 
ADV, DO 
pre, post 
Grilo, Masheb, & 
Wilson (2005c); 




CBT + fluoxetine CBT + 
medication 
26a 16 16 Active, 
placebo 




Grilo, Masheb, & 
Wilson (2005c); 




CBT + placebo CBT + 
placebo 
28a 16 16 Active, 
placebo 
only 




Grilo, Masheb, & 
Salant (2005b) 
Grilo (2005b) CBT guided self-
help + orlistat   
CBT guided 
self-help + 












N nse ttreat Control nc Format Outcomes  Time 
points 
medication 
Grilo et al. (2011) Grilo (2011) 
CBT + WLT 
CBT + behavioral 
weight loss treatment 
CBT + 
WLT 
35a 32 40 Active  Group OBE, ABS, EDP, 
DE, BW, BMI 
pre, post, 
6m, 12m 
Grilo & White 
(2013a) 


















26a  16 Active, 
placebo 
27 Individual OBE, ABS, EDP, 
DE, BW, BMI 
pre, post, 
6m, 12m 
Grilo et al. (2014) Grilo (2014) 
unguided self-
help + placebo 
CBT unguided self-





25a  16 Active, 
placebo 
only 
27 Individual OBE, ABS, EDP, 
DE, BW, BMI 
pre, post, 
6m, 12m 
Le Grange et al. Le Grange CBT + ecological CBT + other 19a 12 12 Active  Group OBE REM, EDP, pre, post, 








N nse ttreat Control nc Format Outcomes  Time 
points 





DE, BMI, DO 12m 
Masheb et al. 
(2011) 
Masheb 
(2011) CBT + 
diet 




25a 16.8 26 Active  Individual ABS, DO pre, post, 
6m, 12m 
Masheb et al. 
(2011) 
Masheb 
(2011) CBT + 
counseling 




25a 19.1 26 Active  Individual ABS pre, post, 
6m, 12m 
Molinari et al. 
(2005) 
Molinari 
(2005) CBT + 
WLT 
CBT + diet  CBT + 
WLT 
22 42 54 Active  Group + 
individual 
DO pre, post 
Molinari et al. 
(2005) 
Molinari 
(2005) WLT + 
Diet + fluoxetine WLT + 
medication 
22 18 54 Active  Group + 
individual 
OBE, ADV, DO pre, post 








N nse ttreat Control nc Format Outcomes  Time 
points 
fluoxetine 
Molinari et al. 
(2005) 
Molinari 
(2005) CBT + 
WLT + 
fluoxetine 
CBT + diet + 




21 42 54 Active  Group + 
individual 
ADV, DO pre, post 




 26 Placebo 146 Individual OBE, EDP, BW, 
DO 
pre, post 
Pendleton et al. 
(2002) 
Pendleton 
(2002) CBT + 
WLT   
CBT + exercise CBT + 
WLT 
28 16 17 Active  Group OBEd ABS, DE pre, post, 
6m, 12m 
Pendleton et al. 
(2002) 
Pendleton 
(2002) CBT + 
WLT 
maintenance 




29 28 43 Active  Group OBEd ABS, DE pre, post, 
6m 








N nse ttreat Control nc Format Outcomes  Time 
points 
Ricca et al. (2001) Ricca (2001) 
CBT + 
fluoxetine 
CBT + fluoxetine CBT + 
medication 




Ricca et al. (2001) Ricca (2001) 
CBT + 
fluvoxamine 
CBT + fluvoxamine CBT + 
medication 




Ricca et al. (2009) Ricca (2009) 
CBT + 
zonisamide 
CBT + zonisamide CBT + 
medication 




Inpatient treatment            









30a 15 6 Active  Group + 
individual 
































31a  15 6 Active  Group + 
individual 











29a  6 Active  Group + 
individual 












N nse ttreat Control nc Format Outcomes  Time 
points 
Riva et al. (2003) Riva (2003) 
inpatient 





9 5 6 Active  Group ABS, BW pre, post, 
6m 













9 15 6 Active  Group + 
individual 




Riva et al. (2003) Riva (2003) 
inpatient + 
CBT 
Inpatient weight loss 






9 15 6 Active  Group ABS, BW pre, post, 
6m 
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Notes. CBT, cognitive-behavioral therapy; IPT, interpersonal psychotherapy; DBT, dialectical behavior therapy; MBAT, mindfulness-based 
awareness training; WLT, behavioral weight loss treatment; number of patients in treatment condition; nse, number of sessions; ttreat treatment 
duration in weeks; nc, number of patients in inactive control condition; OBE, number of objective binge-eating episodes; OBEd, number of days 
with objective binge-eating episodes; ABS, abstinence from binge eating; REM, remission from binge-eating disorder; EDP, eating disorder 
psychopathology; DE, depression; QOL, quality of life; BW, body weight; BMI, body mass index; ADV, adverse events; DO, reasons for drop-out 
from treatment; pre, pre-treatment; post, post-treatment; 3m, 3-month follow-up etc. Listed outcomes refer to analyzed data of the post-treatment 
assessment only. 
aIntent-to-treat data. bComparison between treatment group and control group examined at post-treatment only because follow-up data were 
confounded with them. cIn Carter & Fairburn (1998), data of the wait-list control group not used because of confounding with those of treatment 
group.  
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B-1 
Table B1 
Study characteristics: Active conditions with sample size per treatment category (k/n) in randomized-controlled trials (RCT). 
 Total  
  
Psychotherapy 43/1535 
Cognitive-behavioral therapy 36/1218 
Interpersonal psychotherapy 2/156 
Psychodynamic therapy 1/48 
Humanistic therapy 1/51 
Other psychotherapy 3/62 
Self-help treatment 14/498 
Guided self-help treatment 8/340 
Cognitive-behavioral guided self-help treatment 7/323 
Other guided self-help treatment 1/17 
Unguided self-help treatment 6/158 
Cognitive-behavioral unguided self-help treatment 5/143 
B-2 
 Total  
  
Other unguided self-help treatment 1/15 
Pharmacotherapy 30/1469 
Second generation antidepressants 14/328 
Central nervous system stimulants 7/628 
Anticonvulsants 3/255 
Other pharmacotherapy 6/258 
Behavioral weight loss treatment 7/277 
Diet 0/0 
Exercise 1/44 
Diet, exercise 1/64 
Diet, exercise, behavioral strategies 5/169 
Self-help weight loss treatment 3/53 
Pharmacological weight loss treatment 5/232 
Combined treatment 30/934 
B-3 
 Total  
  
Cognitive-behavioral therapy + pharmacological interventions 6/150 
Cognitive-behavioral therapy + behavioral weight loss treatment 8/236 
Cognitive-behavioral therapy + behavioral weight loss treatment + pharmacological interventions 5/105 
Behavioral weight loss treatment + pharmacological interventions 4/118 
Other combined treatment 7/225 
Inpatient treatment 6/117 
Multimodal inpatient binge-eating disorder and weight loss treatment 4/79 
Multimodal inpatient weight loss treatment 2/38 
Note. Treatment format: psychotherapy, group format: 29, individual format: 12, group plus individual format: 2; self-help treatment, group format: 
4, individual format: 9, group plus individual format: 1; behavioral weight loss treatment, group format: 5, individual format: 2; self-help weight 
loss treatment, individual format: 3; combined treatment, group format: 11, individual format: 14, group plus individual format: 5; inpatient 
treatment: group format: 2, group plus individual format: 4. 
C-1 
 
Table C1  
Sample characteristics 
 Psycho- Self-help  Pharmaco-  Weight loss treatment Combined  Inpatient  
 therapy treatment therapy Behavioral Self-help Pharmaco-
logical 
treatment treatment 
















Age, years 43.8 ± 10.8 
(33/1509) 
45.7 ± 10.8 
(10/536) 
40.2 ± 10.4 
(28/2682) 
42.5 ± 9.4 
(6/294) 
46.0 ± 9.2 
(1/38) 
41.1 ± 10.0 
(3/417) 
42.1 ± 15.3 
(25/1076) 
31.8 ± 7.8 
(4/99) 
Body weight, kg 101.2 ± 22.2 
(11/503) 
100.3 ± 14.0 
(1/66) 
101.5 ± 20.8 
(23/2405) 
101.3 ± 17.8 
(6/274) 
- 101.2 ± 18.7 
(4/445) 
104.8 ± 17.1 
(13/619) 




37.0 ± 7.6 
(28/1276) 
36.0 ± 6.4 
(12/532) 
36.3 ± 6.4 
(29/2702) 
36.8 ± 5.2 
(6/294) 
36.0 ± 6.6 
(1/38) 
36.4 ± 5.7 
(2/357) 
37.7 ± 6.0 
(23/609) 




15.0 ± 10.3 
(23/865) 
19.4 ± 12.8 
(10/485) 
22.8 ± 12.7 
(29/2702) 
19.5 ± 14.0 
(4/193) 
13.0 ± 10.8 
(3/61) 
14.2 ± 9.6 
(3/385) 
18.2 ± 14.6 
(18/737) 
- 
Binge-eating 14.7 ± 7.2 16.1 ± 7.2 17.8 ± 5.2 15.6 ± 6.8 11.3 ± 7.2 12.8 ± 5.0 15.0 ± 7.6 - 
C-2 
 
 Psycho- Self-help  Pharmaco-  Weight loss treatment Combined  Inpatient  
 therapy treatment therapy Behavioral Self-help Pharmaco-
logical 
treatment treatment 
days, n (15/902) (4/349) (19/2319) (3/116) (2/23) (3/384) (4/215) 
Duration of 
BED, years 
17.9 ± 10.5 
(10/337) 
- 18.0 ± 10.7 
(7/594) 





14.8 ± 5.3 
(43/1940) 
11.1 ± 5.5 
(9/503) 
- 19.3 ± 6.9 
(6/233) 
5.3 ± 0.6 
(3/61) 
- 21.8 ± 9.4 
(23/624) 





16.5 ± 7.8 
(43/1940) 
12.2 ± 6.6 
(14/676) 
13.7 ± 6.0 
(30/2722) 
23.3 ± 6.9 
(7/310) 
12.0 ± 0.0 
(3/61) 
14.4 ± 6.1 
(5/465) 
26.0 ± 12.2 
(30/1224) 
6.0 ± 0.0 
(6/117) 
Note. Displayed are M ± SD and (k, number of study arms / n, number of participants). 
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95% CI Z  p k/n Fail-safe N  τ2 Q(df), pQ I2 (%) 
Psychotherapy          
Binge-eating episodes 0.83 
(9.5) 
0.45 - 1.20 
(5.6 - 13.4) 
4.3 < .001 12/672 28 0.29 35(11), < .001 79 
Binge-eating abstinence 9.9 5.4 - 18.3 7.3 < .001 12/721 63 0.30 14(11), .25 33 
Eating disorder 
psychopathology 
0.54 0.26 - 0.82 3.8 < .001 11/719 21 0.15 34(10), < .001 70 
Depression 0.44 0.29 - 0.59 5.8 < .001 11/719 14 0.00 4(10), .94 0 
Body weight (kg) 0.15 
(1.9) 
-0.11 - 0.40 
(-1.3 - 5.2) 
1.1 .26 3/236 0 0.00 0(2), .95 0 
Body mass index (kg/m2) 0.09 
(0.4) 
-0.11 - 0.29 
(-0.4 - 1.3) 





95% CI Z  p k/n Fail-safe N  τ2 Q(df), pQ I2 (%) 
Drop-out 1.88 1.13 - 3.14 2.4 0.015 13/842 8 0.31 19(12), .078 38 
Self-help treatment          
Binge-eating episodes 0.68 
(6.6) 
0.25 - 1.12 
(3.4 - 9.8) 
3.1 .0021 10/554 20 0.29 22(9), .0084 78 
Binge-eating abstinence 8.5 3.1 - 23.1 4.2 < .001 7/502 38 0.84 15(6), .024 60 
Eating disorder 
psychopathology 
0.57 0.15 - 0.99 2.7 .008 6/353 14 0.13 15(5), .0097 63 
Depression 0.36 -0.74 1.9 .054 5/293 7 0.08 8(4), .093 51 
Body mass index (kg/m2) 0.02 
(0.2) 
-0.22 - 0.26 
(-0.1 - 0.6) 
0.2 .87 5/308 0 0.00 4(4), .39 0 
Drop-out 2.08 1.17 - 3.71 2.5 .013 7/383 3 0.00 5(6), .55 7 
Pharmacotherapy          





95% CI Z  p k/n Fail-safe N  τ2 Q(df), pQ I2 (%) 
(3.5) (2.2 - 4.9) 
Binge-eating abstinence 1.9 1.4 - 2.8 3.6 < .001 24/2627 17 0.39 53(23), < .001 66 
Eating disorder 
psychopathology 
0.20 -0.42 1.9 .058 13/1216 4 0.07 26(12), .010 60 
Depression 0.14 -0.29 1.9 .064 10/788 0 0.00 11(9), .27 2 
Body weight (kg) 0.48 
(2.3) 
0.23 - 0.73 
(1.3 - 3.3) 
3.8 < .001 13/616 31 0.16 43(12), < .001 65 
Body mass index (kg/m2) 0.41 
(1.5) 
0.23 - 0.58 
(1.1 - 1.9) 
4.6 < .001 11/1086 3 0.03 14(10), .15 34 
Drop-out 1.19 0.88 - 1.62 1.1 .26 23/2498 0 0.16 36(22), .032 42 
Self-help weight loss treatment         
Binge-eating episodes 0.32 
(3.3) 
-0.19 - 0.83 
(-1.2 - 7.9) 







95% CI Z  p k/n Fail-safe N  τ2 Q(df), pQ I2 (%) 
Pharmacological weight loss treatment        
Binge-eating episodes 0.47 
(3.5) 
0.02 - 0.92 
(-0.1 - 7.0) 
2.1 .039 3/354 3 0.09 4(2), .12 53 
Binge-eating abstinence 2.2 1.5 - 3.2 3.9 < .001 4/424 5 0.00 1(3), .79 0 
Eating disorder 
psychopathology 
0.64 -1.65 1.5 .12 4/421 12 0.60 13(3), .0052 91 
Depression 0.34 -1.02 1.3 .19 2/113 2 0.06 2(1), .17 46 
Body weight (kg) 0.89 
(3.6) 
0.19 - 1.58 
(0.8 - 6.5) 
2.5 .012 5/448 12 0.50 21(4), < .001 87 
Body mass index (kg/m2) 0.38 
(1.2) 
0.16 - 0.59 
(0.5 - 1.9) 
3.5 < .001 2/344 1 0.00 0(1), .96 0 
Drop-out 0.67 0.45 - 1.00 -2.0 .051 5/465 - 0.00 3(4), .52 0 





95% CI Z  p k/n Fail-safe N  τ2 Q(df), pQ I2 (%) 
Binge-eating episodes 0.27 
(3.7) 
-0.03 - 0.58 
(1.7 - 5.7) 
1.7 .082 6/532 0 0.06 10(5), 0.087 56 
Binge-eating abstinence 1.8 0.8 - 3.8 1.5 .13 7/409 3 0.41 9(6), 0.16 57 
Eating disorder 
psychopathology 
0.27 0.09 - 0.45 2.9 .0035 4/468 2 0.00 0(3), 0.97 0 
Depression 0.24 0.00 - 0.47 2.0 .046 4/287 1 0.00 2(3), 0.53 1 
Body weight (kg) 0.54 
(3.6) 
0.35 - 0.74 
(1.6 - 5.6) 
5.4 < .001 3/412 3 0.00 0(2), 0.84 0 
Drop-out 0.88 0.58 - 1.33 -0.6 .53 5/576 - 0.01 4(4), 0.38 5 
aMean differences are calculated as treatment minus control where the mean within each group is pre-treatment minus post-treatment. Displayed 
are standardized values and 95% confidence interval (CI), and raw values and 95% CI in parentheses. Odds ratios use the control arm as 
reference. I2, total heterogeneity; k, number of pairs of study arms; n, number of patients; Q, test statistic of heterogeneity; τ2, estimated total 
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Figure D1. Forest plots for pre-treatment to post-treatment change in binge-eating episodes in randomized-
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Figure D2. Forest plots for the odds of abstinence from binge eating at post-treatment in randomized-controlled 
trials with inactive control
E-1 
Table E1 





95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
Psychotherapy – Cognitive-behavioral therapy        
Binge-eating episodes 0.87 
(9.2) 
0.42 - 1.33 
(5.2 - 13.2) 
3.8 < .001 11/655 26 0.41 35(10), < .001 85 
Binge-eating abstinence 10.0 5.3 - 18.6 7.2 < .001 11/651 58 0.36 14(10), .19 36 
Eating disorder 
psychopathology 
0.65 0.37 - 0.93 4.6 < .001 9/593 23 0.11 21(8), .0073 63 
Depression 0.44 0.28 - 0.61 5.3 < .001 9/593 14 0.00 3(8), .91 0 
Body weight (kg) 0.15 
(1.9) 
-0.11 - 0.40 
(-1.3 - 5.2) 
1.1 .26 3/236 0 0.00 0(2), .95 0 





95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
(0.6) (-0.4 - 1.6) 
Dropout 2.2 1.1 - 4.1 2.4 .018 10/654 9 0.39 15(9), .094 40 
Self-help treatment - Cognitive-behavioral therapy self-help treatment      
Binge-eating episodes 0.74 
(7.6) 
0.40 - 1.08 
(4.5 - 10.7) 
4.3 < .001 19/1159 39 0.29 54(18), < .001 81 
Binge-eating abstinence 9.0 5.3 - 15.3 8.1 < .001 18/1153 95 0.43 39(17), .0019 43 
Eating disorder 
psychopathology 
0.54 0.32 - 0.76 4.9 < .001 13/889 26 0.08 29(12), .0034 58 
Depression 0.35 0.20 - 0.49 4.7 < .001 12/829 12 0.01 9(11), .62 20 
Body weight (kg) 0.15 
(1.9) 
-0.11 - 0.40 
(-1.3 - 5.2) 
1.1 .26 3/236 0 0.00 0(2), .95 0 
Body mass index (kg/m2) 0.05 
(0.2) 
-0.12 - 0.22 
(-0.4 - 0.9) 





95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
Dropout 2.3 1.5 - 3.5 3.8 < .001 15/976 11 0.12 17(14), .26 18 
Pharmacotherapy – Lisdexamfetamine        
Binge-eating episodes 0.65 
(6.0) 
0.39 - 0.92 
(-0.2 - 12.1) 
4.9 < .001 4/425 6 0.00 9(3), .033 0 
Binge-eating abstinence 3.1 2.0 - 5.0 4.8 < .001 6/1165 9 0.00 7(5), .26 0 
Body weight (kg) 0.94 
(3.2) 
0.63 - 1.25 
(2.2 - 4.2) 
5.9 < .001 2/178 5 0.00 0(1), .55 0 
Body mass index (kg/m2) 0.22 
(0.9) 
0.00 - 0.44 
(0.0 - 1.7) 
2.0 .047 7/322 0 0.00 3(6), .76 0 
Dropout 1.0 0.7 - 1.4 -0.1 .88 4/953 - 0.00 0(3), .96 0 
aMean differences are calculated as treatment minus control where the mean within each group is pre-treatment minus post-treatment. Displayed 
are standardized values and 95% confidence interval (CI), and raw values and 95% CI in parentheses. Odds ratios use the control arm as 
reference. I2, total heterogeneity; k, number of pairs of study arms; n, number of patients; Q, test statistic of heterogeneity; τ2, estimated total 
heterogeneity in random effects models. 
 F-1 
Table F1 





95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
Comparative effectiveness across treatment categories        
Psychotherapy versus Self-help treatment         
Binge-eating episodes 0.15 
(2.1) 
-0.43 - 0.74 
(-4.7 - 9.0) 
0.5 .61 4/308 - 0.24 12(3), .0059 80 
   3-6 months 0.17 
(1.4) 
-0.68 - 1.03 
(-6.7 - 9.5) 
0.4 .69 4/206 - 0.60 20(3), < .001 87 
   6-12 months -0.00 
(-0.5) 
-0.59 - 0.58 
(-6.8 - 5.8) 
-0.0 .99 4/206 - 0.21 10(3), .017 71 
Binge-eating abstinence 2.1 0.9 - 4.8 1.8 .068 4/308 0 0.22 7(3), .079 39 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months 0.7 0.4 - 1.1 -1.5 .13 5/308 - 0.00 1(4), .96 0 
Eating disorder 
psychopathology 
0.10 -0.11 - 0.32 1.0 .33 5/449 0 0.00 1(2), .70 0 
   3-6 months 0.20 -0.08 - 0.48 1.4 .16 4/308 2 0.00 1(3), .73 0 
   6-12 months -0.02 -0.24 - 0.19 -0.2 .83 5/449 0 0.00 3(4), .55 0 
Depression 0.16 -0.12 - 0.43 1.1 .27 4/308 0 0.00 2(3), .54 0 
   3-6 months 0.25 -0.03 - 0.52 1.7 .080 4/308 4 0.00 2(3), .60 0 
   6-12 months 0.09 -0.19 - 0.36 0.6 .53 4/308 0 0.00 1(3), .75 0 
Body weight (kg) 0.11 
(1.0) 
-0.22 - 0.44 
(-2.0 - 4.0) 
0.6 .52 1/141 0 - - - 
Body mass index (kg/m2) -0.07 
(-0.2) 
-0.29 - 0.15 
(-1.0 - 0.7) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   3-6 months 0.10 
(0.7) 
-0.26 - 0.47 
(-1.2 - 2.5) 
0.6 .58 4/206 0 0.02 4(3), .24 16 
   6-12 months 0.21 
(1.0) 
-0.12 - 0.55 
(-0.6 - 2.6) 
1.2 .21 4/206 0 0.00 1(3), .86 0 
Drop-out 0.2 0.1 - 0.4 -5.0 < .001 6/627 - 0.00 4(5), .56 0 
Psychotherapy versus Pharmacotherapy         
Binge-eating episodes 1.67 
(8.6) 
0.98 - 2.37 
(5.6 - 11.6) 
4.7 < .001 2/66 10 0.00 1(1), .41 0 
   6-12 months 1.87 
(9.6) 
0.93 - 2.81 
(5.6 - 13.5) 
3.9 < .001 2/66 11 0.19 3(1), .071 52 
Body mass index (kg/m2) 0.50 
(1.5) 
-0.10 - 1.10 
(-0.2 - 3.2) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months 0.69 
(2.1) 
0.08 - 1.29 
(0.4 - 3.8) 
2.2 .027 2/66 3 0.00 0(1), .85 0 
Drop-out 0.5 0.1 - 2.1 -0.9 .35 2/83 - 0.00 0(1), .80 0 
Psychotherapy versus Behavioral weight loss treatment        
Binge-eating episodes 0.34 
(3.0) 
0.03 - 0.64 
(0.3 - 5.6) 
2.2 .030 2/170 1 0.00 0(1), .70 0 
   3-6 months 0.32 
(3.5) 
-0.14 - 0.77 
(-1.4 - 8.4) 
1.4 .17 1/76 1 - - - 
   6-12 months 0.26 
(2.9) 
-0.19 - 0.71 
(-2.0 - 7.8) 
1.1 .26 1/76 0 - - - 
Binge-eating abstinence 1.2 0.7 - 2.2 0.6 .56 4/346 0 0.18 6(3), .13 46 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months 1.9  1.0 - 3.4 2.1 .040 3/225 4 0.03 2(2), .34 11 
Eating disorder 
psychopathology 
0.27 0.05 - 0.48 2.5 .014 4/346 3 0.00 2(3), .55 0 
   3-6 months 0.26 -0.12 - 0.64 1.3 .19 2/107 1 0.00 0(1), .84 0 
   6-12 months 0.21 -0.05 - 0.48 1.6 .12 3/225 0 0.00 0(1), .92 0 
Depression 0.19 -0.08 - 0.47 1.4 .17 3/207 1 0.00 1(2), .57 0 
   3-6 months 0.11 -0.27 - 0.49 0.5 .58 2/107 0 0.00 1(1), .35 0 
   6-12 months -0.00 -0.38 - 0.38 -0.0 .99 2/107 0 0.00 0(1), .88 0 
Body weight (kg) -0.46 
(-5.5) 
-0.98 - 0.07 
(-12.1 - 1.0)  
-1.7 .086 2/229 - 0.10 4(1), .054 73 
   3-6 months -0.25 
(-3.1) 
-0.70 - 0.21 
(-8.8 - 2.6) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months -0.19 
(-2.5) 
-0.64 - 0.26 
(-8.1 - 3.2) 
-0.8 .40 1/76 0 - - - 
Body mass index (kg/m2) -0.57 
(-1.6) 
-0.96 - -0.19 
(-2.4 - -0.8) 
-3.0 .0032 3/309 - 0.07 5(2), .074 63 
   3-6 months -0.24 
(-0.8) 
-0.69 - 0.22 
(-2.3 - 0.7) 
-1.0 .31 1/76 - - - - 
   6-12 months -0.12 
(-0.4) 
-0.57 - 0.33 
(-1.9 - 1.1) 
-0.5 .61 1/76 - - - - 
Drop-out 0.6 0.2 - 1.4 -1.2 .23 4/346 - 0.46 7(3), .067 59 
Psychotherapy versus Combined treatment      
Binge-eating episodes -0.10 
(-1.0) 
-0.35 - 0.15 
(-2.9 - 0.9) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   3-6 months -0.17 
(-1.8) 
-0.66 - 0.31 
(-6.9 - 3.3) 
-0.7 .48 1/67 - - - - 
   6-12 months -0.00 
(-0.0) 
-0.30 - 0.29 
(-2.1 - 2.1) 
-0.0 .98 5/199 0 0.00 0(4), .99 0 
Binge-eating abstinence 0.8 0.3 - 2.1 -0.4 .71 1/80 0 - - - 
   3-6 months 0.8 0.4 - 1.6 -0.6 .54 3/194 - 0.00 2(2), .32 0 
   6-12 months 0.5 0.0 - 5.4 -0.6 .56 2/137 - 2.68 8(1), .0037 88 
Eating disorder 
psychopathology 
-0.24 -0.60 - 0.12 -1.3 .18 2/121 -  0.00 0(1), .99 0 
   3-6 months -0.34 -0.82 - 0.15 -1.4 .17 1/67 - - - - 
   6-12 months -0.19 -0.55 - 0.17 -1.0 .30 2/121 - 0.00 0(1), .64 0 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   3-6 months 0.05 -0.27 - 0.36 0.3 .78 3/194 0 0.00 0(2), .78 0 
   6-12 months -0.10 -0.39 - 0.20 -0.7 .51 3/178 - 0.00 1(2), .70 0 
Body weight (kg) -0.51 
(-4.7) 
-1.42 - 0.39 
(-11.7 - 2.4) 
-1.1 .27 3/120 - 0.43 8(2), .015 75 
   3-6 months -0.05 
(-0.6) 
-0.53 - 0.43 
(-6.4 - 5.1) 
-0.2 .83 1/67 - - - - 
   6-12 months -0.02 
(-0.3) 
-0.50 - 0.46 
(-5.9 - 5.4) 
-0.1 .93 1/67 - - - - 
Body mass index (kg/m2) -0.17 
(-0.8) 
-0.46 - 0.12 
(-1.9 - 0.3) 
-1.2 .24 7/281 - 0.03 8(6), .21 19 
   3-6 months -0.06 
(-0.2) 
-0.54 - 0.42 
(-1.8 - 1.4) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months -0.11 
(-0.5) 
-0.41 - 0.19 
(-1.6 - 0.6) 
-0.7 .47 5/199 - 0.00 4(4), .46 0 
Drop-out 0.5 0.3 - 0.9 -2.2 .029 5/235 - 0.00 0(4), .99 0 
Self-help treatment versus Behavioral weight loss treatment       
Binge-eating days 0.08 
(0.8) 
-0.26 - 0.43 
(-2.4 - 4.0) 
0.5 .63 1/130 0 - - - 
Binge-eating abstinence 1.2 0.6 - 2.4 0.5 .61 1/130 0 - - - 
   6-12 months 2.0 0.9 - 4.4 1.7 .086 1/107 1 - - - 
Eating disorder 
psychopathology 
0.25 -0.09 - 0.60 1.4 .15 1/130 1 - - - 
   6-12 months 0.35 -0.04 - 0.73 1.8 .076 1/107 1 - - - 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
(-3.4) (-7.1 - 0.3) 
Body mass index (kg/m2) -0.47 
(-1.3) 
-0.82 - -0.12 
(-2.3 - -0.3) 
-2.6 .0084 1/130 - - - - 
Drop-out 1.1 0.5 - 2.4 0.3 .78 1/130 0 - - - 
Self-help treatment versus Self-help weight loss treatment      
Binge-eating episodes 0.13 
(1.6) 
-0.32 - 0.59 
(-3.7 - 6.9) 
0.6 .56 1/75 0 - - - 
Binge-eating abstinence 4.7 1.7 - 12.8 3.1 .0022 1/75 3 - - - 
Eating disorder 
psychopathology 
0.14 -0.31 - 0.60 0.6 .53 1/75 0 - - - 
Depression 0.03 -0.43 - 0.48 0.1 .91 1/75 0 - - - 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
(-1.2) (-2.8 - 0.4) 
Drop-out 0.3 0.1 - 1.0 -2.0 .042 1/75 - - - - 
Pharmacotherapy versus Combined treatment        
Binge-eating episodes -0.94 
(-8.2) 
-1.65 - -0.24 
(-10.9 - -5.5) 
-2.6 .0086 4/174 - 0.34 12(3), .0093 76 
   3-6 months -0.35 
(-4.8) 
-0.94 - 0.23 
(-12.2 - 2.7) 
-1.2 .24 2/70 - 0.00 0(1), .93 0 
   6-12 months -0.98 
(-8.5) 
-1.79 - -0.18 
(-11.8 - -5.2) 
-2.4 .017 4/136 - 0.46 11(3), .0097 77 
Binge-eating abstinence 0.1 0.0 - 0.5 -3.2 .0013 2/108 - 0.00 0(1), .75 0 
   3-6 months 0.1 0.0 - 0.7 -2.2 .025 2/108 - 0.00 1(1), .38 0 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
Eating disorder 
psychopathology 
-0.55 -1.02 - -0.08 -2.3 .023 2/108 - 0.00 0(1), .98 0 
   3-6 months -0.91 -1.40 - -0.43  -3.7 < .001 2/108 - 0.00 0(1), .53 0 
   6-12 months -0.67 -1.28 - -0.06 -2.2 .030 2/108 - 0.07 3(1), .089 48 
Depression -0.49 -0.96 - -0.02 -2.0 .043 2/108 - 0.00 0(1), .92 0 
   6-12 months -0.31 -0.84 - 0.22 -1.2 .25 1/54 - 0.03 2(1), .17 31 
Body weight (kg) -0.03 
(-0.2) 
-0.56 - 0.49 
(-3.4 - 3.0) 
-0.1 .91 2/84 - 0.00 0(1), .89 0 
Body mass index (kg/m2) -0.35 
(-1.8) 
-0.73 - 0.02 
(-3.2 - -0.4) 
-1.9 .063 4/174 - 0.00 7(3), .085 0 
   3-6 months 1.12 
(3.8) 
0.49 - 1.75 
(1.9 - 5.6) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months -0.17 
(-0.4) 
-1.22 - 0.89 
(-3.9 - 3.0) 
-0.3 .76 4/136 2 0.95 19(3), <.001 88 
Drop-out 1.0 0.5 - 2.3 0.1 .94 4/196 0 0.00 1(3), .92 0 
Behavioral weight loss treatment versus Combined treatment      
Binge-eating episodes 0.36 
(3.2) 
-1.00 - 1.72 
(-11.1 - 17.5) 
0.5 .60 2/151 1 0.91 17(1), < .001 94 
   3-6 months -0.41 
(-5.3) 
-0.89 - 0.07 
(-11.3 - 0.7) 
-1.7 .092 1/69 - - - - 
   6-12 months -0.28 
(-3.6) 
-0.76 - 0.20 
(-9.6 - 2.4) 
-1.1 .25 1/69 - - - - 
Binge-eating abstinence 0.8 0.3 - 2.1 -0.5 .64 3/235 - 0.49 6(2), .061 65 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months 0.7 0.4 - 1.4 -1.0 .33 3/80 -  0.00 1(2), .57 0 
Eating disorder 
psychopathology 
-0.25 -0.55 - 0.05 -1.7 .097 3/226 - 0.00 1(2), .53 0 
   3-6 months -0.63 -1.11 - -0.14  -2.5 .012 1/69 - - - - 
   6-12 months -0.44 -0.92 - 0.05 -1.8 .076 1/69 - - - - 
Depression -0.32 -0.62 - -0.02 -2.1 .035 3/226 - 0.00 0(2), .84 0 
   3-6 months -0.21 -0.69 - 0.27 -0.9 .39 1/69 - - - - 
   6-12 months -0.12 -0.60 - 0.35 -0.5 .61 1/69 - - - - 
Body weight (kg) 0.22 
(2.1) 
-0.14 - 0.59 
(-1.5 - 5.7) 
1.2 .22 4/262 0 0.06 6(3), .091 49 
   3-6 months 0.03 
(0.0) 
-0.32 - 0.37 
(-3.3 - 3.3) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months 0.09 
(0.6) 
-0.25 - 0.42 
(-2.3 - 3.4) 
0.5 .61 2/140 0 0.00 0(1), .55 0 
Body mass index (kg/m2) 0.48 
(1.3) 
0.08 - 0.89 
(-0.2 - 2.9) 
2.3 .020 2/151 2 0.03 2(1), .21 36 
   3-6 months 0.05 
(0.1) 
-0.29 - 0.38 
(-0.9 - 1.0) 
0.3 .78 2/140 0 0.00 1(1), .45 0 
   6-12 months 0.20 
(0.5) 
-0.13 - 0.54 
(-0.4 - 1.4) 
1.2 .23 2/140 0 0.00 1(1), .47 0 
Drop-out  1.5 0.3 - 8.8 0.4 .66 2/151 1 1.22 4(1), .057 72 
Pharmacological weight loss treatment versus Combined treatment       
Binge-eating episodes 0.36 
(6.7) 
-0.15 - 0.88 
(-1.8 - 15.2) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   3-6 months 0.31 
(5.5) 
-0.21 - 0.83 
(-3.1 - 14.1) 
1.2 .25 2/88 1 0.00 0(1), .70 0 
   6-12 months 0.27 
(4.8) 
-0.25 - 0.78 
(-3.8 - 13.5) 
1.0 .31 2/88 0 0.00 1(1), .43 0 
Binge-eating abstinence 2.0 0.7 - 5.6 1.4 .17 2/103 2 0.00 0(1), .94 0 
   3-6 months 0.3 0.1 - 0.9 -2.2 .030 2/103 - 0.00 1(1), .47 0 
   6-12 months 0.3 0.1 - 1.0 -1.9 .060 2/103 - 0.00 0(1), .87 0 
Eating disorder 
psychopathology 
-0.04 -0.51 - 0.43 -0.2 .88 2/103 - 0.00 0(1), .78 0 
   3-6 months -0.29 -0.76 - 0.19 -1.2 .23 2/103 - 0.00 0(1), .75 0 
   6-12 months -0.22 -0.75 - 0.25 -0.9 .36 2/103 - 0.00 0(1), .99 0 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   3-6 months -0.19 -0.66 - 0.28 -0.8 .43 2/103 - 0.00 0(1), .55 - 
   6-12 months -0.20 -0.67 - 0.28 -0.8 .41 2/103 - 0.00 1(1), .46 0 
Body weight (kg) -0.14 
(-1.8) 
-0.69 - 0.42 
(-7.8 - 4.1) 
-0.5 .63 2/89 - 0.02 2(1), .22 21 
   3-6 months -0.06 
(-0.7) 
-0.57 - 0.46 
(-6.4 - 5.0) 
-0.2 .83 2/88 - 0.00 1(1), .39 0 
   6-12 months -0.25 
(-3.1) 
0.77 - 0.27 
(-9.0 - 2.9) 
-0.9 .34 2/88 - 0.00 0(1), .80 0 
Body mass index (kg/m2) -0.12 
(-0.4) 
-0.75 - 0.50 
(-2.4 - 1.5) 
-0.4 .70 2/89 - 0.07 2(1), .12 42 
   3-6 months -0.25 
(-0.8) 
-0.76 - 0.27 
(-2.4 - 0.8) 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months -0.31 
(-1.1) 
-0.83 - 0.21 
(-2.8 - 0.6) 
-1.2 .24 2/88 - 0.00 0(1), .81 0 
Drop-out 1.6 0.5 - 5.3 0.8 .43 2/103 1 0.00 0(1), .95 0 
Comparative effectiveness within treatment categories      
Psychotherapy: CBT versus other psychotherapies       
Binge-eating days 0.26 
(1.4) 
0.01 - 0.50 
(0.2 - 2.7) 
2.1 .040 2/257 0 0.00 1(1), .48 0 
Binge-eating abstinence 1.9 1.0 - 3.6 1.9 .052 3/333 2 0.15 4(2), .16 45 
   3-6 months 1.1 0.4 - 3.1 0.2 .81 1/67 1 - - - 
   6-12 months 1.2 0.7 - 1.9 0.6 .55 3/306 0 0.00 2(2), .33 0 
Eating disorder 
psychopathology 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   3-6 months 0.06 -0.20 - 0.33 0.5 .65 2/218 0 0.00 1(1), .42 0 
   6-12 months 0.08 -0.18 - 0.33 0.6 .56 2/239 0 0.00 0(1), .66 0 
Depression 0.17 -0.37 - 0.71 0.6 .54 2/196 0 0.11 4(1), .055 73 
   3-6 months -0.09 -0.57 - 0.39 -0.4 .71 1/67 - - - - 
   6-12 months 0.20 -0.22 - 0.63 0.9 .34 1/88 1 - - - 
Body weight (kg) 0.07 
(1.0) 
-0.32 - 0.46 
(-4.4 - 6.3) 
0.4 .72 1/101 0 - - - 
Body mass index (kg/m2) -0.03 
(-0.2) 
-0.24 - 0.19 
(-1.0 - 0.6) 
-0.3 .80 3/333 - 0.00 1(2), .74 0 
Drop-out 0.6 0.2 - 1.9 -0.8 .43 4/424 - 0.95 10(3), .021 75 
Psychotherapy: CBT versus humanistic therapy        






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   6-12 months 1.1 0.4 - 2.5 0.1 .91 1/88 0 - - - 
Eating disorder 
psychopathology 
0.30 -0.09 - 0.69 1.5 .13 1/101 1 - - - 
   6-12 months 0.15 -0.27 - 0.57 0.7 .49 1/88 0 - - - 
Depression 0.44 0.05 - 0.84 2.2 .028 1/101 2 - - - 
   6-12 months 0.20 -0.22 - 0.63 0.9 .34 1/88 1 - - - 
Body weight (kg) 0.07 
(1.0) 
-0.32 - 0.46 
(-4.4 - 6.3) 
0.4 .72 1/101 0 - - - 
Body mass index (kg/m2) 0.09 
(0.05) 
-0.30 - 0.48 
(-1.4 - 2.4) 
0.5 .64 1/101 0 - - - 
Drop-out 0.1 0.0 - 0.4 -3.2 .0015 1/101 - - - - 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
Binge-eating days 0.19 
(0.13) 
-0.12 - 0.50 
(-0.8 - 3.4) 
1.2 .23 1/162 0 - - - 
Binge-eating abstinence 1.6 0.8 - 3.5 1.3 .21 1/158 1 - - - 
   6-12 months 0.9 0.5 - 1.8 -0.2 .82 1/151 - - - - 
Eating disorder 
psychopathology 
0.13 -0.17 - 0.44 0.9 .39 1/162 0 - - - 
Body mass index (kg/m2) -0.10 
-0.3 
-0.41 - 0.21 
(-1.2 - 0.6) 
-0.6 .52 1/158 - - - - 
Drop-out 1.3 0.5 - 3.7 0.5 .60 1/162 0 - - - 
          
Psychotherapy: CBT versus psychodynamic therapy        






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
(1.5) (-0.1 - 3.1) 
Binge-eating abstinence 1.1 0.4 - 2.8 0.2 .81 1/74 0 - - - 
   3-6 months 1.1 0.4 - 3.1 0.2 .81 1/67 0 - - - 
   6-12 months 2.4 0.8 - 7.0 1.6 .11 1/67 2 - - - 
Eating disorder 
psychopathology 
0.09 -0.31 - 0.49 0.4 .67 1/95 0 - - - 
   3-6 months -0.10 -0.58 - 0.38 -0.4 .68 1/67 - - - - 
Depression -0.11 -0.51 - 0.29 -0.5 .59 1/95 - - - - 
   3-6 months -0.09 -0.57 - 0.39 -0.4 .71 1/67 - - - - 
Body mass index (kg/m2) -0.04 
(-0.2) 
-0.49 - 0.42 
(-3.1 - 2.7) 
-0.2 .87 1/74 - - - - 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
Self-help treatment: CBT guided self-help versus CBT unguided self-help      
Binge-eating episodes 0.31 
(4.9) 
-0.10 - 0.72 
(-0.3 - 10.1) 
1.5 .14 3/229 2 0.07 4(2), .13 51 
   3-6 months 0.38 
(4.5) 
-0.54 - 1.30 
(-6.3 - 15.4) 
0.8 .42 3/173 2 0.57 11(2), .0049 88 
   6-12 months 0.40 
(4.9) 
-0.53 - 1.33 
(-5.3 - 15.1) 
0.8 .40 2/104 2 0.35 4(1), .041 76 
Binge-eating abstinence 1.6 0.8 - 3.1 1.4 .16 3/229 - 0.03 4(2), .14 8 
   3-6 months 1.2 0.5 - 2.8 0.4 .68 2/104 0 0.00 0(1), .66 0 
   6-12 months 1.2 0.5 - 2.7 0.4 .72 2/104 1 0.00 1(1), .47 0 
Eating disorder 
psychopathology 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
   3-6 months 0.08 -0.22 - 0.38 0.5 .61 3/173 0 0.00 0(2), 1.0 0 
   6-12 months 0.06 -0.33 - 0.44 0.3 .77 1/104 0 0.00 0(1), .61 0 
Depression 0.19 -0.42 - 0.80 0.6 .54 2/160 1 0.12 2(1), .12 58 
   3-6 months 0.07 -0.32 - 0.45 0.3 .74 2/104 0 0.00 0(1), .57 0 
   6-12 months 0.12 -0.32 - 0.56 0.5 .58 2/104 1 0.20 1(1), .28 15 
Body mass index (kg/m2) 0.10 
(0.3) 
-0.17 - 0.36 
(-0.7 - 1.4) 
0.7 .47 3/229 - 0.00 2(2), .31 0 
   3-6 months 0.08 
(0.2) 
-0.22 - 0.38 
(-1.1 - 1.5) 
0.5 .62 3/173 - 0.00 3(2), .27 0 
   6-12 months 0.07 
(0.2) 
-0.32 - 0.45 
(-1.6 - 2.0) 
0.3 .74 2/104 - 0.00 1(1), .42 0 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
Self-help treatment: CBT unguided self-help versus self-compassion training unguided self-help    
Binge-eating days 0.44 
(2.7) 
-0.31 - 1.19 
(-1.6 - 7.0) 
1.2 .25 1/28 1 - - - 
Eating disorder 
psychopathology 
-0.61 -1.37 - 0.15 -1.6 .11 1/28 - - - - 
Depression -0.43 -1.18 - 0.32 -1.1 .26 1/28 - - - - 
Body mass index (kg/m2) -0.68 
(-0.4) 
-1.44 - 0.09 
(-0.8 - 0.0) 
-1.7 .082 1/28 - - - - 
Drop-out 0.2 0.0 - 2.4 -1.2 .22 1/28 - - - - 
          
Pharmacotherapy: Fluoxetine versus other second generation antidepressants      






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
(-2.3) (-6.3 - 1.8) 
   6-12 months -0.53 
(-3.0) 
-1.23 - 0.18 
(-6.8 - 0.8) 
-1.5 .14 1/32 - - - - 
Binge-eating abstinence 0.5 0.1 - 2.3 -0.9 .38 1/31 - - - - 
Eating disorder 
psychopathology 
0.24 -0.37 - 0.85 0.8 .44 1/42 1 - - - 
Depression -0.09 -0.70 - 0.51 -0.3 .76 1/42 - - - - 
Body weight (kg) -0.18 
(-0.2) 
-0.89 - 0.52 
(-3.0 - 2.6) 
-0.5 .61 1/31 - - - - 
Body mass index (kg/m2) -0.06 
(-0.2) 
-0.55 - 0.43 
(-1.4 - 1.1) 
-0.2 .81 2/63 - 0.00 0(1), .81 0 






95% CI Z  p k/n Fail-
safe N  
τ2 Q(df), pQ I2 (%) 
(-0.3) (-2.3 - 1.7) 
Drop-out 0.9 0.3 - 2.3 -0.3 .76 2/85 - 0.00 0(1), .95 0 
 
aMean differences are calculated as treatment minus control where the mean within each group is pre-treatment minus post-treatment or follow-
up. Displayed are standardized values and 95% confidence interval (CI), and raw values and 95% CI in parentheses. Odds ratios use the control 
arm as reference. I2, total heterogeneity; k, number of pairs of study arms; n, number of patients; Q, test statistic of heterogeneity; τ2, estimated 




Moderator analyses for pre-treatment to post-treatment change versus inactive control  
Between-group comparisons Point estimatea 95% CI  Q(df) p k/n 
Treatment format (reference: individual therapy)      
Binge-eating episodes Group: 0.27 -0.02 - 0.57 3.4(1) .064 52/3860 
Binge-eating abstinence Group: 4.78 2.39 - 9.57 19.5(1) < .001 55/4758 
Duration of treatment (reference: shorter therapies, i.e. < 10 weeks)     
Binge-eating episodes Longer therapies: -0.28 -0.52 - -0.04 5.2(1) .023 53/3880 
Binge-eating abstinence Longer therapies: 1.18 0.61 - 2.23 0.2(1) .63 55/4758 
Mode of recruitment (reference: clinical)      
Binge-eating episodes Population-based: 0.30 
Mixed: 0.18 
0.05 - 0.56 
-0.06 - 0.43 
5.5(2) .063 37/2658 
Binge-eating abstinence Population-based: 2.27 
Mixed: 2.21 
1.09 - 4.75 
0.98 - 5.02 
5.5(2) .064 40/3396 
Age (per decade)      
Binge-eating episodes -0.29 -0.51 - 0.07 6.7(1) .0095 39/3465 
G-2 
 
Between-group comparisons Point estimatea 95% CI  Q(df) p k/n 
Binge-eating abstinence 0.79 0.36 - 1.73 0.3(1) .56 41/4146 
Sex (reference: ≥ 90% women)      
Binge-eating episodes < 90% women: -0.20 -0.37 - -0.03 5.3(1) .021 46/3641 
Binge-eating abstinence < 90% women: 0.74 0.49 - 1.12 2.0(1) .16 48/4390 
Body mass index (per kg/m2)      
Binge-eating episodes -0.046 -0.076 - -0.016 8.8(1) .0013 44/3310 
Binge-eating abstinence 0.93 0.84 - 1.01 2.8(1) .092 45/4292 
Number of binge-eating episodes at baseline (per episode/28 days)     
Binge-eating episodes 0.024 0.003 - 0.044 5.2(1) .023 53/3880 
Binge-eating abstinence 1.01 0.96 - 1.06 0.1(1) .77 48/4360 
Type of analysis (reference: intent-to-treat)      
Binge-eating episodes Completer: 0.16 -0.13 - 0.44  1.2(1) .28 53/3880 
Binge-eating abstinence Completer: 1.55 0.81 - 2.94  1.8(1) .19 55/4758 
Time-frame of assessment (reference: binge eating last week)     
Binge-eating episodes Last 4 weeks: -0.15 -0.38 - 0.08 1.6(1) .20 53/3880 
G-3 
 
Between-group comparisons Point estimatea 95% CI  Q(df) p k/n 
Binge-eating abstinence Last 4 weeks: 1.43 0.79 - 2.60 1.4(1) .24 53/4676 
Method of assessment (reference: interview)      
Binge-eating episodes Questionnaire: 0.04 
Diary: 0.52 
-0.25 - 0.34 
0.16 - 0.88 
8.0(2) .019 52/3565 
Binge-eating abstinence Questionnaire: 1.87 
Diary: 1.10 
Recall: 0.84 
0.62 - 5.64 
0.49 - 2.45 
0.13 - 5.67 
1.3(3) .73 52/4366 
Risk of bias (reference: low risk according to Cochrane)     
Binge-eating episodes Unclear risk: 0.22 
High risk: 0.33 
-0.11 - 0.54 
-0.02 - 0.67 
3.5(2) .18 53/3819 
Binge-eating abstinence Unclear risk: 1.42 
High risk: 1.32 
0.62 - 3.22 
0.53 - 3.27 
0.7(2) .70 54/4700 
Blinding (reference: blinded trial)      
Binge-eating episodes Uncertain if blinded: 0.26 
Not blinded: 0.38 
0.02 - 0.51 
-0.09 - 0.86 
5.3(2) .072 37/2912 
G-4 
 
Between-group comparisons Point estimatea 95% CI  Q(df) p k/n 
Binge-eating abstinence Uncertain if blinded: 1.12 
Not blinded: 4.16 
0.56 - 2.27 
0.96 - 18.01 
3.8(2) .15 41/3728 
aChange in standardized difference of mean differences or multiplicative factor in odds ratio compared to the reference category. Cochrane, 






































































































































































Agras et al. (1994) ? ? + ? - + - + + 
Agras et al. (1995) ? ? + ? ? ? - + ? 
Alfonsson et al. (2015) - ? + ? + + - + + 
Allen & Craighead (1999) ? + + ? ? + - + + 
Appolinario et al. (2003) - - - - - - - ? - 
Arnold et al. (2002) ? - - - ? ? - ? ? 




































































































































































Brambilla et al. (2009) ? ? - - + + ? + + 
Brownley et al. (2013) ? ? ? ? ? - ? + ? 
Carter & Fairburn (1998) - - + ? - ? - ? - 
Cassin et al. (2008) - - - + + ? ? + + 
Cesa et al. (2013) - ? ? + ? + + + + 
Devlin et al. (2005) ? ? ? ? - ? ? ? ? 
de Zwaan et al. (2005) ? ? + + ? + ? + + 
de Zwaan et al. (2017) - - + + - - - ? - 




































































































































































Duarte et al. (2017) ? ? + + ? + ? + + 
Ferrer-Garcia et al. (2017) - ? + + ? ? ? + + 
Golay et al. (2005) - - - - ? ? - - ? 
Gorin et al. (2003) ? ? + ? ? + - + + 
Grilo & Masheb (2005a) - - + + ? ? - ? ? 
Grilo et al. (2005b) - - - - - - - ? - 
Grilo et al. (2005c) - - - ? ? ? - ? - 
Grilo et al. (2011) - ? + + ? ? - ? ? 




































































































































































Grilo et al. (2013b) - ? + ? - - - + - 
Grilo et al. (2014) - - ? - - ? - ? - 
Guerdjikova et al. (2008) - - - - ? ? - + ? 
Guerdjikova et al. (2009) - - - - ? + - + + 
Guerdjikova et al. (2012) - - - - ? ? - + ? 
Guerdjikova et al. (2016) - - - - ? - - ? - 
Hilbert & Tuschen-Caffier (2004) ? ? ? + - ? - + ? 
Hudson et al. (1998) ? ? - - ? ? ? + + 




































































































































































Kristeller et al. (2014) ? ? + ? ? + + + + 
Le Grange et al. (2002) ? ? ? + ? ? - ? ? 
Leombruni et al. (2008) ? ? ? ? ? + - + + 
Levine et al. (1996) ? ? + ? ? ? + + + 
Lewer et al. (2017) - ? + + ? + ? + + 
Masheb et al. (2011) - - ? ? ? + + ? + 
Masson et al. (2013) - ? + + - - ? + ? 
McElroy et al. (2000)  ? ? ? ? ? - ? + ? 




































































































































































McElroy et al. (2003b)  ? ? - ? - - - ? ? 
McElroy et al. (2006)  - ? - ? ? - - ? ? 
McElroy et al. (2007a) - ? - ? ? ? - + ? 
McElroy et al. (2007b) - ? ? - ? ? - ? ? 
McElroy et al. (2011) - - ? - ? ? - + ? 
McElroy et al. (2013)  - - - - - + - + + 
McElroy et al. (2015a) - - - - ? ? - + ? 
McElroy et al. (2015b)  - ? - ? ? ? ? + ? 




































































































































































McElroy et al. (2015c)  - ? - ? ? ? - + ? 
Milano et al. (2005) ? ? ? ? ? - + + + 
Molinari et al. (2005) ? ? ? + ? ? + + + 
Munsch et al. (2007) ? ? + + + - - + + 
Nauta et al. (2000) ? ? ? + ? ? - + ? 
Pataky et al. (2013) - - - - ? - ? + + 
Pearlstein et al. (2003) ? ? ? ? - + + + + 
Pendleton et al. (2002) ? ? ? ? ? + - + + 




































































































































































Peterson et al. (2009) - - + + - ? - + - 
Preuss et al. (2017) - ? ? + - - - ? ? 
Ricca et al. (2001) ? + + ? ? - ? + + 
Ricca et al. (2009) ? ? + + ? - ? + ? 
Ricca et al. (2010) - - + + - ? - ? - 
Riva et al. (2003) ? ? + ? - + + + + 
Safer et al. (2010) ? ? ? + ? - ? ? ? 
Stunkard et al. (1996) - ? ? ? ? + ? + + 




































































































































































Telch et al. (2001) ? ? + ? + + - ? + 
Wagner et al. (2016) - - + + + - - + + 
White & Grilo (2013) ? - - ? ? ? - ? ? 
Wilfley et al. (2002) ? ? ? ? ? ? - ? ? 
Wilfley et al. (2008) - ? - ? ? ? - + + 
Wilson et al. (2010) - ? + + - ? ? ? ? 
Note. Items from the Cochrane Risk of Bias Tool. “+” indicates high risk of bias, “?” indicates unclear risk of bias, and “-“ indicates low risk of bias 
in the respective domain. Because the risk of bias was assessed for studies with published full-text only, studies by Hilbert et al., Navia et al. (2017), 
Richard et al., Schag et al., and Yu et al. (2017) were excluded from the rating.  
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Figure I1. Funnel plot for pre-treatment to post-treatment change in binge-
eating episodes in randomized-controlled trials with inactive control 
  
Figure I2. Funnel plots for post-treatment odds of abstinence in randomized-
controlled trials with inactive control (top: small effects, bottom: large effects). 
 
 
